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ABSTRACT 
 
 Recombinant protein vaccines are fast becoming the focus of the vaccine industry 
due to their increased safety.  Here we examine the development of several recombinant 
protein vaccines and the challenges involved.  Once an antigen is identified, and a 
process to recombinantly produce the protein established, the first step is to perform a 
biophysical characterization of the macromolecule.  The proteins were stressed with 
respect to variables such as temperature and pH and monitored for perturbations in 
physical structure indicating potential sources of instability.   Next, we examined aspects 
of formulation such as excipient screening and adjuvant adsorption which may enhance 
the antigen immunogenicity and stability.  The third step involved evaluating the working 
formulation in an animal model to establish dose dependency and the effect of the 
adjuvant.  Finally, accelerated and real-time stability studies are being completed, and the 
formulations adjusted accordingly. 
We begin with three analogous mutant proteins from the pathogenic bacteria 
Shigella flexneri, Burkholderia pseudomallei and Salmonella typhimurium.  All three 
species rely on a type III secretion system (TTSS), commonly referred to as a 
supramolecular injectisome, for virulence.  This macromolecular complex is composed of 
25 or more proteins which form basal and extracellular domains, and shares gross 
architectural similarities with bacterial flagella.  The extracellular component or ‘needle 
complex’, previously identified as a potential vaccine target, is primarily composed of a 
single monomeric subunit organized in a helical array to form a hollow pore which 
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protrudes from the bacterial membrane.  Results of the biophysical characterization 
studies indicate that the secondary structure is largely α-helical in all three proteins, and 
surprisingly thermally labile with transition midpoints in the range of 35-50 oC over the 
pH range of 3-8.  Second derivative UV absorbance spectroscopy data indicates some 
disruption of the protein’s tertiary structure occurs at temperatures in the range of 29-46 
oC.  It appears, that at physiological temperatures, all three proteins experience 
intermediate nonnative molten globule like states in which they display significant 
secondary structure in the absence of extensive tertiary interactions.  These antigens are 
found to be thermally stabilized by the presence of carbohydrates and polyols, and 
additionally all adsorb readily to aluminum hydroxide apparently through hydrogen 
bonds and/or Van der Waals forces.  We have found that the interaction of the proteins 
with the adjuvant changes with time resulting in varying extents of irreversible binding.  
Peptide maps of desorbed protein, however, suggest that chemical changes are not 
responsible for this irreversibility.  We also demonstrate the ability of MxiHΔ5 and PrgIΔ5 
to elicit strong humoral immune responses in a murine model when administered as three 
intramuscular injections.  When administered as monomers, the needle components 
exhibited strong dose dependent behavior, while the polymerized version (shown only for 
MxiH) was exceptionally immunogenic at low doses.   
The second system described here is a recombinant ricin vaccine.  There is an 
urgent need for the development of protective countermeasures against the use of ricin 
toxin as a bioterrorism agent due to its ease of access and distribution as well as its low 
lethal dose.  We describe here the characterization of the stability of RiVax®, an 
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aluminum salt adsorbed recombinant ribotoxin A-chain double mutant, and optimization 
of adjuvant-antigen interactions which has allowed us to produce a stable vaccine that 
displays strong immunogenicity in mice.  We used front face fluorescence as a physical 
measure of protein stability and monitored the adsorbed product upon storage at various 
temperatures.  Indications of protein unfolding were observed and in the most extreme 
cases correlated with a decrease in immunogenicity of the vaccine.  By adding phosphate 
anion, we are able to prevent the conformational changes, and maintain immunogenicity 
of the vaccine during long term storage.   
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Chapter 1 
 
Introduction 
 
 2 
1.1  History 
 
The initial origin and continued development of the field of vaccinology is truly 
remarkable.  The earliest practice of variolation is attributed to a group of 7th century 
Indian Buddhists who drank the venom of poisonous snakes, which may have been a 
toxoid-like product, to become immune to its effect [1].  Some time later, in 11th century 
China, it was observed that prior smallpox exposure often protected humans against 
future acquisition of the disease and thus it became common practice to place variola 
scabs in the nose as a preventative measure [2, 3].  Other sources attribute the original 
smallpox variolation practices to India, but despite the origin it quickly spread to many 
nations as noted by Voltaire below [2, 3].   
 
“The Circassians perceived that of a thousand persons hardly one was 
attacked twice by full blown spallpox; that in truth one sees three or 
four mild cases but never two that are serious and dangerous; that in a 
word one never truly has that illness twice in life.” 
-Voltaire, “On Variolation,” Philosophical Letters, 1734. 
 
The same practice was in fact used by George Washington, who insisted that the men of 
his Continental Army undergo smallpox variolation treatment prior to encounters with 
their largely immune English opponents [4].  Although revolutionary, variolation 
practices were quite crude and involved intentionally transmitting disease in order to 
confer protection.  As a result, a number of people died from the ‘protective’ treatment 
[5].   
 3 
The next major discovery in vaccinology was made by Edward Jenner in 1798, 
when he discovered that immunity against smallpox could be produced in those 
inoculated with cowpox, a mild illness in humans [6].  He also discovered that cowpox 
could be transmitted from person-to-person thereby enabling mass protection against 
deadly outbreaks [6].  Louis Pasteur succeeded Jenner in the summer of 1879 when he 
discovered an alternative to person-to-person vaccination strategies based on a similar 
concept of using a weakened form of the disease to induce immunity [7].  He was 
working on the chicken cholera bacterium at the time and discovered that an aged 
attenuated culture was protective [7].  He further concluded that this type of vaccination 
was safer because it was less likely, relative to treatment with a related organism, to 
transmit other disease.  He also applied this approach to anthrax and rabies illnesses in 
1885 [8].  Despite success, Pasteur was met with resistance in attempting to transfer this 
application from animals to humans because of the public fear of injecting a ‘weakened’ 
toxic material [9].  Pasteur’s expertise was developed further in 1886 by Daniel Elmer 
Salmon and Theobald Smith who used heat to kill typhoid, cholera and plague organisms 
and proposed the resulting material as vaccines with increased safety because they were 
no longer virulent [10].  The rights to the discovery of this technique however were 
disputed due to similar yet subsequent discoveries in the laboratory of Pasteur, who was 
widely famous at the time [3].  Then, in the early 1900’s, toxoids against diphtheria and 
tetanus, which could be prepared by treating the toxins with formalin at 37 oC, were 
found to be protective by a number of scientist including Gaston Ramon who created the 
first human vaccination [11, 12].   
 4 
In the roughly 100 years following Jenner’s 1798 discoveries, the field of 
vaccinology flourished, and the ensuing 100 years were no different.  The application of 
cell culture and a greater understanding of immunology supplemented a rapidly growing 
field that saw the invention of vaccines against Yellow Fever, Pertussis, Influenza, 
Typhus, Polio, Measles, Mumps, Adenovirus, Varicella, Japanese Encephalitis, Hepatitis 
A, Meningitis, Pneumococcus and Haemophilius influenzae type b [5].  Additionally, 
mass vaccination campaigns led by the World Health Organization (WHO) completely 
eliminated naturally occurring smallpox in the year 2005 and are currently focused on the 
eradication of polio [3,13,14].  It is now well recognized that the prevention of disease 
through vaccination, if possible, is far more effective than post-infection treatment.  This 
sentiment is well stated by vaccinologist Stanley Plotkin: 
“The impact of vaccination on the health of the world’s peoples is hard to 
exaggerate.  With the exception of safe water, no other modality, not even 
antibiotics, has had such a major effect on mortality’s reduction and 
population growth.”  
   
 
1.2  Definition 
 
By definition, a vaccine is a biological preparation which may include peptides, 
proteins, polysaccharides, polynucleotides, viruses and other whole organisms that 
establishes or improves immunity to a particular disease [15].  The word carries with it a 
deliberate history as it was adapted from Edward Jenner’s 1798 discovery that when 
administered to humans, cow pox (variolæ vaccinæ) would protect against smallpox [15].  
As indicated above, there are many different types of routinely used vaccines, and many 
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more in various stages of development.  Each vaccine type has noted advantages and 
disadvantages associated with both its application to certain organisms as well as its use 
in humans.   
 
1.2.1  Live, Attenuated 
Vaccines composed of live attenuated organisms contain the entire disease 
causing organism and thus are intrinsically extremely potent.  These vaccines are able to 
stimulate both the humoral and cellular immune systems often resulting in life-long 
protection after just one dose [3].  Although the vaccine has been attenuated through 
exposure to heat, chemicals or radiation, there is a small likelihood that the agent may not 
be completed altered or may revert to its virulent form [3, 15].  For this reason, attenuated 
vaccines are some of the most dangerous and are rarely given to immuno-compromised 
patients who are the most likely to contract the illness from a small number of untreated 
or reverted organisms [15].  Another disadvantage of live attenuated vaccines is the 
common requirement that they be refrigerated before use to maintain biological activity 
[15].  This is extremely problematic for developing countries where a cold-chain may not 
be available for the entire transport route. 
 
1.2.2  Killed, Inactivated 
Vaccines which are referred to as killed or inactivated typically consist of 
formaldehyde or heat treated organisms or toxoids which cannot revert to their virulent 
form [15].  This type of vaccine is known to generate a weaker immune response relative 
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to live attenuated versions because only the humoral immune system is stimulated.  They 
are notably safer, but may require administration of several doses to ensure protection 
[15].  Killed inactivated vaccines are regarded as being easier to store relative to live 
attenuated vaccines because they can often be lyophilized [15].   
 
1.2.3  Conjugated 
 A conjugate vaccine refers to one in which a poor immunogen is covalently 
linked to a carrier protein.  The antigen is typically a bacterial polysaccharide such as that 
seen on the surface of Haemophilus influenzae B (HiB), Streptococcus pneumoniae or 
Nesseria meningitis which are considered poor antigens in children because they are 
Thymus cell independent (TI) and therefore do not induce the necessary opsinizing 
antibodies [3].  Through their association with a Thymus cell dependent (TD) carrier 
protein, the most common of which are tetanus and diptheria toxoids, they confer the 
proper protective response [3].  
 
1.2.4  Subunit 
 Subunit vaccines are considered the safest; however they are also far less 
immunogenic than attenuated or killed vaccines because they represent only a portion of 
the organism and therefore do not stimulate the immune system to the extent that a whole 
organism vaccine does [3, 15].  Subunit vaccines are composed of purified antigens 
which have been identified for their ability to stimulate the immune system, but are not 
infectious and thus are far less likely to induce unfavorable immune related side effects.  
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FDA approved examples of this approach are the Hepatitis B and Human Papillomavirus 
Vaccines; however a great number of vaccines using this approach are currently under 
investigation.  Recently, the vaccine industry has focused largely on subunit vaccines due 
to their increased safety profile and the ability to manufacture them recombinantly in 
large quantities in a reproducible manner [3, 15].  One major challenge associated with 
their use, however, is their decreased antigenicity relative to whole cell vaccines which is 
often insufficient for protection.  As a result, several booster doses are often required and 
may decrease patient compliance.  Additionally, a vaccine adjuvant is almost always 
required.   
 
1.3  Subunit Vaccine Development 
Discussion herein will pertain to the development of several recombinant protein 
subunit vaccines.  Therefore, we will discuss in greater detail those problems commonly 
encountered in this arena of vaccinology and the strategies used to overcome them.  For 
example, as mentioned above, recombinant subunit vaccines are typically only weakly 
immunogenic relative to their whole cell counterparts due to their inability to stimulate 
both humoral and cellular immune responses.  Their intrinsic immunogenicity is humoral 
in nature and mainly represented by the production of specific opsinizing antibodies [3].  
Production of a protective response by a recombinant subunit vaccine often requires 
administration of several doses as well as the presence of an adjuvant [3].  A second 
challenge stems from the intrinsic instability of biomolecules as well as the criticality of 
antigen conformation to generate proper immune recognition.  Close attention must be 
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paid to the stability of subunit vaccine antigens to ensure biological activity is sustained 
throughout storage until the point of administration. 
 
1.3.1  Adjuvant Use 
 As a result of their decreased immunogenicity, subunit vaccines typically require 
the presence of adjuvant to elicit a protective immune response.  When co-administered 
with an antigen, an adjuvant increases the specific immune response to the antigen 
without having any specific antigenic activity itself.  Currently, only two adjuvants, both 
aluminum salts, are approved by the United States Food and Drug Administration (FDA) 
for human use, although novel adjuvants are a hot topic of current research and are in 
clinical development [16-18].  Aluminum salt adjuvants are suspensions of particles with 
highly charged surfaces which have been precipitated in the presence of selected anions.  
Aluminum hydroxide is described in the literature as consisting of aggregates of poorly 
crystalline material approximately 3 µm in size [19-21].  Its point-of-zero (PZC) charge 
is approximately 11 which means that at neutral pH, the particle surface is characterized 
by a net positive charge [21, 22].  Aluminum phosphate, precipitated in the presence of 
phosphate ions, is amorphous in nature and is slightly larger in size at approximately 4-5 
µm [19-21].  Its corresponding PZC is lower than that observed for aluminum hydroxide, 
but can range from 5-7 [21, 22].  As a result, at neutral pH the material is negatively 
charged.  The charged surface character of these substances facilitates an electrostatic 
interaction with proteins of the opposite charge, although forces such as hydrophobic 
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interactions, hydrogen bonds and Van der Waals forces may also be involved in their 
surface interactions [22].   
  Aluminum salts are commonly referred to as immunopotentiators due to their 
ability to prime the immune system.  After nearly 100 years of investigation and use, 
however, their exact mechanism of action is still unclear.  Several mechanisms have been 
suggested, and it appears that their actual complex course of action may be a combination 
of several factors and may be dependent on both the injection route as well as the antigen.  
The two most widely accepted mechanisms of action are that of depot formation 
and enhanced targeting to antigen presenting cells (APCs).  When injected, aluminum 
adsorbed vaccines disperse slowly from the site of injection due to their particulate nature 
resulting in a depot which produces sustained release of antigen [23-27].  Additionally, 
the adsorbed antigens are more likely to be targeted for uptake by APCs due to their 
increased size relative to soluble antigens [23-26, 28].  Aluminum salt particles are in the 
range of 5 µm and macrophages are known for their ability to target and phagocytose 
particulate material up to 10 µm [29].   
The third mechanism is broadly referred to as immunopotentiation, and over time 
many groups have hypothesized and investigated specific mechanisms of such proposed 
activity.  More specifically, one group found that aluminum salts are toxic to nearby cells 
causing them to induce the secretion of uric acid, resulting in recruitment of monocytes to 
the site of injection.  This is suggested to result in more efficient antigen processing [30, 
31].  Similarly, others proposed that aluminum salts induce a local inflammatory immune 
response that attracts immunocompetent cells and thereby enhances the antigen specific 
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immune response [32-34].  Still another group hypothesized that aluminum salts activate 
the complement system.  Studies in which the aluminum salt and antigen were 
administered separately, at locations remote from one another were presented as support 
for this systemic theory [35].   
Historically, the major disadvantage to the use of aluminum salt adjuvants is their 
inability to stimulate the cell mediated responses.  Several groups have, however, 
proposed that by adding selected interleukins, both humoral and cellular responses can be 
initiated [36, 37].  Additionally, the instability of aluminum salts to lyophilization has 
limited their use in a number of formulations.  It has been shown recently, however, that 
provided an optimized cycle is developed, it is possible to lyophilize aluminum salts 
without observing gross aggregation of the product [38].  Other disadvantages include 
stimulation of IgE (allergic) mediated responses, erythema and/or contact 
hypersensitivity and the inability of the adjuvants to boost responses for all antigens [19]. 
The most widely recognized advantage to the use of aluminum salt adjuvants is 
the induction of higher, faster and longer antibody responses to a primary immunization 
using small, antigenically weak synthetic or recombinant antigens [39].  It is also 
recognized that the presence of an aluminum salt adjuvant may reduce the amount of 
antigen or number of injections required to elicit a protective response [17, 19, 25].  
Thus, drug companies can include less antigen per dose enabling production of a greater 
number of doses.  Additionally, aluminum salt adjuvants are recognized for their ability 
to improve efficacy of vaccines in newborns, elderly and otherwise immuno-
compromised patients [17, 19, 25].   
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It is currently unclear exactly which formulation factors, degree of adsorption, 
dose of adjuvant and/or strength of this interaction, are the most important for 
immunogenicity of adsorbed antigen.  It is hypothesized that optimal conditions may vary 
depending on the antigen.  For example, FDA regulations require that adult tetanus and 
diptheria toxoid be >75% adsorbed [40], however vaccines with low adsorption (<50%) 
have been used effectively and meet all regulatory requirements [19].  Additionally, some 
research suggests that in order to attain an optimal effect, excess free adjuvant must be 
present [41,42].  There appears, however, to be a critical maximum level above which the 
antigen specific immune response is decreased [43-45].  This phenomenon may be a 
result of antigen masking [25] or perhaps macrophage toxicity [46].  More recently, it has 
been established that the strength of adsorption affects the immunogenicity [47, 48].  
Specifically, results from these studies indicate that immunogenicity is decreased if the 
antigen is too tightly bound to the adjuvant.  Thus, there are a number of factors 
influencing efficacy of an adsorbed antigen, and each must be evaluated thoroughly to 
ensure optimal efficacy of each vaccine product. 
 
1.3.2  Protein Stability 
Proteins and peptides are the most common constituents of subunit vaccines.  
Although simple in structure relative to whole virus vaccines, proteins are associated with 
an array of both chemical and structural problems due to their dynamic character and the 
presence of higher order structure.  Biomolecules used in vaccines must remain within 
established stability parameters to eliminate the potential for adverse effects on 
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antigenicity.  A loss in biological activity is often the result of aggregation or adsorption 
to the walls of the storage container, epitope loss, or decreased uptake and processing by 
the immune system.  By studying the physical and chemical stability of proteins we can 
learn about their potential sources of instability and take pro-active formulation steps to 
prevent them. 
Proteins are charged polymers with distinct primary, secondary, tertiary and 
sometimes quaternary structure.  Primary structure involves the amino acid sequence, 
while the secondary structure involves local interactions of the peptide backbone leading 
to structures such as helices and sheets.  Tertiary structure describes the interaction of 
secondary structural elements to form a distinct three dimensional shape while quaternary 
structure defines the interaction among protein monomers, each with tertiary structural 
elements.  Every aspect of structure is influenced by changes in solution conditions such 
as pH, ionic strength and temperature.  The pH of a solution, for example, impacts the 
charge state of individual amino acid side chains and therefore their interaction with other 
residues and the solvent to form secondary, tertiary and possibly quaternary structure.  
Additionally, pH can affect chemical degradation reactions which can alter the protein 
primary sequence and therefore higher order structural elements.  Changes in ionic 
strength can alter solubility and can also directly affect protein structure and stability by 
weakening electrostatic interactions which contribute to protein structure through charge 
pair formation.  The effects of temperature on protein folding and stability are also 
important.  As temperature is increased, bonds responsible for maintaining protein 
structure may be weakened leading to either reversible or irreversible protein unfolding.  
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Additionally, just as in the case of pH, some chemical degradation reactions are promoted 
by elevated temperatures and may result in protein degradation.  As mentioned above, it 
is critical to vaccine efficiency that the stability profile for a proposed vaccine antigen be 
thoroughly characterized and well understood in order to propose formulation conditions 
which can reproducibly maintain antigenicity. 
In many cases, biological assays such as immunogenicity in animals are key to 
studying vaccine stability.  While necessary, biological assays do not provide information 
regarding the source or origin of instability.  Thus, it is imperative that chemical and 
physical techniques be used to enable the development of formulations based on specific 
case-by-case behavior.   
The chemical integrity of a protein is often examined using high-performance 
liquid chromatography (HPLC) in one of several formats (reversed phase, hydrophobic 
interaction, ion-exchange or size exclusion).  These techniques allows for the sensitive 
detection of changes in polarity, charge or size, which are often the result of chemical 
modifications.  Additionally, one can couple HPLC columns to mass spectrometers to 
identify the nature of the chemical change as well as its location in the protein primary 
structure. 
Biophysical techniques enable one to evaluate various structural aspects of 
proteins which often result in unfolding, aggregation or other adverse events.  X-ray 
crystallography and NMR are commonly used to elucidate high resolution three 
dimensional structures which greatly aide studies of structural stability.  It is also possible 
to obtain structures under various solution conditions to investigate the effects of solute 
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concentration, pH or other variables.  The drawback is that these methods are often rather 
time extensive and usually require large amounts of highly purified antigens which are 
not always available during early stages of vaccine development.  Other spectroscopic 
techniques of potential utility in biophysical studies of macromolecular systems are static 
and dynamic light scattering, circular dichroism, intrinsic and extrinsic fluorescence, UV 
absorbance, infrared and Raman spectroscopies and differential scanning and isothermal 
titration calorimetry.  Each technique can be utilized under a range of solution conditions 
to monitor subtle changes in protein conformation and thereby enable analysis of stability 
related phenomenon.  For example, if upon an increase in temperature a protein displays 
a decrease in structural elements, one can presume that unfolding major structural 
alterations are occurring.  Although this represents a somewhat simplistic use of 
spectroscopic techniques, the same approach can be applied in more complex scenarios.  
Light scattering techniques are often used to determine size or molecular weight of a 
protein and thus can be used to monitor unfolding and/or aggregation events.  Circular 
dichroism spectroscopy is used to monitor secondary structure based on the chiral nature 
of secondary structural elements.  Ultraviolet absorbance and fluorescence emission 
spectroscopies are used to define changes in tertiary structural elements by using 
aromatic residues as probes of their surrounding environments.  Infrared and Raman 
spectroscopies focus on characterizing aspects of secondary and tertiary structure based 
on vibrational properties of peptide bonds and side chains.  Calorimetry permits the study 
of the thermal properties of vaccine components in terms of thermally induced structural 
changes (DSC) and interaction between molecular components (ITC).   
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There are several approaches available to prevent or slow changes in protein 
structure during storage and to preserve biological activity.  The most common is the 
addition of compounds such as organic osmolytes which stabilize antigens based on their 
preferential hydration [49].  This phenomenon forces surrounding water molecules to 
pack in a more ordered fashion around the protein surface and thereby discourages 
protein unfolding.  Surfactants can also be used as excipients by interfering with protein 
aggregation and/or surface adsorption [50, 51].  Another commonly utilized stabilization 
technique is lyophilization or freeze drying.  Many biomolecules exhibit enhanced 
stability as dry powders where dynamic motions are restricted.  It is also possible in some 
cases to eliminate the source of instability by point mutating specific residues or deleting 
regions of protein primary structure.  It is important, however, to verify that critical 
epitopes have not been altered if this is necessary.  Another option for protein 
stabilization is to restrict the conformational mobility through disulfide bonds or 
chemical crosslinking.  In all cases, it is imperative to ensure that alterations made do not 
alter antigenicity.  
 
1.4  Specific Aims 
In this work, I will examine the task of developing several recombinant subunit 
proteins as vaccine antigens.  These studies can be divided into several sections each of 
which builds upon previous work.  The first effort was to thoroughly characterize the 
solution stability of a previously selected group of antigens using biophysical methods.  
This was done to identify potential formulation problems as well as define conditions 
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under which the antigen was most stable and therefore suitable for formulation.  The 
second step, which is referred to as pre-formulation, involved the examination of 
formulation parameters such as excipient stabilization adjuvant adsorption.  The third 
portion involved the use of animal models to evaluate the antigenicity of preliminary 
formulations upon which adjustments and improvements were made.  Finally, the final 
step evaluated the stability of the adsorbed formulation using real time and accelerated 
models and correlated the results with animal immune responses.  Final adjustments were 
made based on the results obtained, and clinical work was initiated by collaborators.   
I will present data from each of the steps indicated above.  The data, however, 
pertain to more than one antigen.  The first three chapters present work done on a series 
of analogous mutant proteins, MxiHΔ5, PrgIΔ5 and BsaLΔ5 from three different bacterial 
pathogens while data in the last chapter pertains to rRTA, a single mutated chain from 
ricin toxin.  All antigens discussed here share in common their recombinant subunit 
nature and the need for an adjuvant.  
 
1.4.1  Biophysical Characterization of Needle Proteins 
 The data presented in Chapter 2 is related to the first step in the development 
process described above.  Through the use of several spectroscopic techniques, we 
compiled a set of data representative of the conformational behavior of several antigens 
under conditions of thermal stress and over a pH range of 3-8.  Then, using a previously 
established approach [52-55], we converted the individual data points at each pH and 
temperature condition into a series of vectors and assigned them arbitrary color 
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representations.  When summed, the vectors are represented in the form of a multi-
colored phase diagram which enables the identification of solution conditions under 
which the antigen remains stable, and those which induce structural changes. 
  
1.4.2  Pre-formulation of Needle Proteins 
 Chapter 3 details pre-formulation experiments which were designed using 
information acquired in the biophysical characterization step.  We screened each of the 
antigens for thermal stabilization by a group of “generally regarded as safe” (GRAS) 
compounds and then investigated the strength and nature of their interactions with both 
aluminum phosphate and aluminum hydroxide adjuvants.  We also established 
accelerated and real time stability studies of the adsorbed formulation to examine the 
effect of storage temperature and duration on the adsorbed material.   
 
1.4.3  Immunogenicity of Needle Proteins 
 In this chapter (4), we present data obtained from several murine immunogenicity 
studies.  The purpose of this work was to confirm the hypothesized immunogenicity of 
the antigens, investigate the effect of dose on the magnitude of the response as well as 
examine the adjuvant affect, if any. 
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1.4.4  Adsorbed stability studies of rRTA 
 Chapter 5 describes a number of accelerated and real-time stability studies, and 
the exploration of a correlation between a physical and a biological assay.  This chapter 
also contains work on the optimization of adjuvant-antigen interactions through 
modulation of the adjuvant surface.   
 
 
1.4.5  Summary and Conclusions 
 
The last chapter (6) serves as a summary of concepts and findings discussed 
herein.  Suggestions for future work are also discussed.   
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2.1  Introduction 
A variety of gram negative bacterial pathogens including Shigella flexneri, 
Salmonella typhimurium, Burkholderia pseudomallei, Yersinia enterocolitica, and 
Pseudomonas aeruginosa are responsible for an array of diseases including dysentery, 
gastroenteritis, typhoid fever and mellioidosis ranging in intensity from mild to lethal.  
Such diseases are common in developing nations where sources of food and water are 
commonly contaminated, but have also been implicated in cases of intentional exposure 
within the United States [1].  Despite attempts, there is currently no commercially 
available vaccine for any of the aforementioned pathogens.  Each year, Shigella alone 
continues to infect more than 165 million people resulting in greater than 1.1 million 
deaths (http://www.who.int/vaccine_research/diseases/shigella/en/). 
Essential to the virulence of these bacteria is their multi-component type III 
secretion system (TTSS), which mediates the specific secretion and translocation of 
virulence factors via a supramolecular structure.  This surface localized protein complex 
is evolutionarily related to bacterial flagella [2,3].  Morphologically, this “syringe-like” 
structure consists of 25 or more unique proteins, and spans the bacterial membranes, 
extracellular space and host cellular membrane [2].   Direct physical contact between the 
bacterium and target cell allows the specific secretion and translocation of effector 
proteins into the cytosol of the target cell to interfere with host cell signaling processes 
[4, 5].  Although the syringe apparatus is morphologically similar and functionally 
conserved among the aforementioned bacteria, the constituent and secreted proteins vary 
among the different species [3]. 
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The exposed filamentous portion of the TTSS, commonly referred to as the 
“needle”, is approximately 60 nm long, and is comprised of approximately 120 copies of 
a monomeric subunit arranged in a superhelical array [6-8].  A pore approximately 2-3 
nm in diameter lines the needle, and effectively connects the bacterial cytoplasm to the 
target host cell membrane [4-5].  The tip of the needle is composed of an invasion 
plasmid antigen (Ipa) protein unique to each bacterium [9].  Upon exposure to bile salts, 
this tip protein has been shown to specifically recruit a second unique Ipa protein which 
localizes distal to the needle tip [10].  It is possible that direct contact with the host cell 
by the distal protein represents the initiation of an activation pathway for the virulent 
invasion of the target cell.  Transmission of the activation signal is suspected to pass 
through the helical needle structure, occurring by an unknown mechanism which may 
involve slight changes in the packing of the needle while maintaining the helical 
parameters defining the structure [6]. 
The monomeric subunits of the helical needle are small (~10 kDa), hydrophilic 
proteins with low isoelectric points (<5). Recent developments in structural studies of the 
acidic needle proteins indicate that their surfaces are characterized by distinct patches of 
positive and negative charge (Figure 2.1) [11].  This observation suggests that 
electrostatic interactions might be intimately involved in needle assembly, and 
consequently that changes in pH and/or ionic strength might affect this process [11].  
Despite significant conservation in primary sequence (Figure 2.2), however, the three 
proteins do not share similar distributions of surface charge [11].   
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Figure 2.1 Shown for (A) MxiHΔ5 (PDB # 2CA5), (B) BsaLΔ5 (PDB # 2G0U) and (C) 
PrgIΔ5 (PDB # 2JOW) is a protein ribbon structure overlaid with a solvent accessible 
surface map colored according to electrostatic potential where the color red denotes 
negatively charged regions and blue positively charged.  Structures on the right panel 
represent a 180 degree rotation about the y axis.  The surface electrostatic potential maps 
were calculated using APBS [44], and visualized using PyMol 
(http://pymol.sourceforge.net). 
A. 
C. 
B. 
N 
C 
C 
C N
2 
 
N 
 28 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MxiH  MSVT----VPNDDW--TLSSLSETFDDGTQTLQGELTLALDKLAKNPSNPQLLAEYQSKL 54 
PrgI  MATP----WSG-----YLDDVSAKFDTGVDNLQTQVTEALDKLAAKPSDPALLAAYQSKL 51 
BsaL  MSNPPTPLLADYEWSGYLTGIGRAFDDGVKDLNKQLQDAQANLTKNPSDPTALANYQMIM 60 
   
MxiH  SEYTLYRNAQSNTVKVIKDVDAAILEHHHHHH 86 
PrgI  SEYNLYRNAQSNTVKVFKDIDAAILEHHHHHH 83 
BsaL  SEYNLYRNAQSSAVKSMKDIDSSILEHHHHHH 92 
   
 
 
Figure 2.2 Primary sequence alignment of MxiH, BsaL and PrgI as acquired from the 
ClustalW server.   
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 This suggests that the protein-protein interactions responsible for needle formation may 
differ from bacterium to bacterium [11].  For example, while all three proteins form 
similar two helix bundles, the electrostatic potential seen in PrgIΔ5 is such that positively 
charged regions are located ~90 degrees from the oppositely charged face, whereas for 
BsaLΔ5 and MxiHΔ5, the orientational difference is approximately ~180 degrees (Figure 
2.1).  Furthermore, the negative face is oriented along the surface of the two helix bundle 
in BsaLΔ5 and MxiHΔ5 while in PrgIΔ5 the most significant region of negative charge is 
located away from the helix interface along the side of the structure (Figure 2.1).  The 
presence of significant basic character on the surface of acidic proteins such as MxiHΔ5, 
BsaLΔ5 and PrgIΔ5 further suggests that electrostatic interactions may be an integral 
component of needle polymerization, although higher resolution structures of 
polymerized needles will be necessary to confirm this [11]. 
Needle formation is suspected to take place in a stepwise manner in which, upon 
receiving the proper signal, subunits are secreted through the central channel of the basal 
body and polymerize at the growing distal tip [2,12].  The channel passing though the 
basal body and extending into the needle complex has an inner diameter of approximately 
20-30 Å, and therefore does not appear able to accommodate fully folded proteins [4, 6, 
13].  Thus, it probably secretes proteins in structurally altered forms [6]. 
Both the monomeric and oligomerized needle forms of the subunit proteins are 
promising vaccine candidates due to their presence on the bacterial membrane surface 
during the initial stages of infection by the pathogens.  It is suspected that an 
oligomerized form of the protein will initiate a more robust immunological response as 
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compared to the monomeric subunits.  This hypothesis is supported by literature 
concerning protein aggregates in which a correlation between increased antigen 
molecular weight and repetitive organization of the structure results in an enhanced 
immune response [14-17].  Furthermore, recent studies indicate that immunization of 
mice with the recombinant YscF needle protein provide protection against challenge with 
Yersinia pestis [18]. 
 In their full length form, the monomeric proteins have a strong tendency to 
oligomerize and self-associate.  Consequently, a soluble C terminal truncated variant 
which maintains native secondary structure while inhibiting needle polymerization was 
used for spectroscopic work shown here [19].  Even with this modification, however, 
both YscF (Yersinia pestis) and PscF (Pseudomonas aeruginosa) rapidly self associate 
upon expression and purification (unpublished results), and as a result were not suitable 
for characterization using the methods described in this paper. 
Here we report a detailed study of the effect of temperature and pH on the 
mutated monomeric subunit proteins MxiHΔ5 (Shigella), PrgIΔ5 (Salmonella), and BsaLΔ5 
(Burkholderia).  Additionally, the behavior of the needle proteins under such conditions 
may shed light on the mechanism of needle assembly.  To facilitate a detailed 
characterization of the three non-polymerizing proteins, an empirical phase diagram 
(EPD) technique was employed [20-27].  In this method, proteins are represented as 
vectors in a highly dimensioned experimental space.  As previously shown, EPDs are 
useful tools when large quantities of data are required for a comprehensive analysis of 
stability behavior. 
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2.2  Materials and Methods 
 
2.2.1 Materials 
Expression of the C terminal truncated versions of the needle proteins has been 
described previously [8, 19, 28].  The plasmid for each of the soluble variants was 
expressed in E. coli BL21 (DE3), and induced for overexpression [29].  Recombinant 
proteins were purified by means of a C terminal His6 tag according to previously 
documented methods [30, 31].  The C terminal Δ5 variants were dialyzed against 20 mM 
citrate-phosphate buffer in preparation for spectroscopic analysis.  The citrate-phosphate 
buffer (20 mM) was prepared over a pH range of 3-8 using citric acid monohydrate 
(Fisher Scientific, Pittsburgh, PA) and anhydrous dibasic sodium phosphate (Sigma, St. 
Louis, MO).  The ionic strength of each buffer solution was not adjusted to a constant 
value across the pH range.  All spectroscopic studies employed protein concentrations of 
0.15 to 0.25 mg/mL based on extinction coefficients of 9,970, 11,460 and 12,950 M-1cm-1 
at 280 nm for MxiH, PrgI and BsaL respectively.  Extinction coefficients were obtained 
using Protparam on the Expasy server (http://www.expasy.ch/tools /protparam.html). 
 
2.2.2  High Resolution UV Absorbance Spectroscopy 
Ultraviolet absorbance temperature studies were conducted over a pH range of 3-
8 at one unit intervals using an Agilent 8453 UV-Visible diode array spectrophotometer.  
Individual spectra were collected every 2.5 oC from 10 to 80 oC following a 5 min. 
equilibration at each temperature, sufficient for equilibrium to be reached.  Solution 
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turbidity was simultaneously analyzed by monitoring the optical density at 350 nm as a 
function of temperature.  All second derivative UV absorbance and optical density data 
are presented as mean values (N=3).  Chemstation software (Agilent) was employed to 
generate second derivatives of the zero-order UV spectra from 200 to 400 nm using a 
nine-point data filter.  The resulting spectra were fit to a third-order polynomial using the 
Savitsky-Golay method, and smoothed with 99 points of interpolation to obtain effective 
high resolution (+/- 0.01 nm).  The resultant spectra contained six negative peaks, 
representing well established contributions from the three aromatic amino acids (Phe, 
Tyr, and Trp) [24].  Peak positions were identified as a function of temperature and 
plotted in Microcal Origin (version 7.0) as previously described [31].  When applicable, 
midpoints of thermal transition were determined using the sigmoidal fit function in the 
Microcal Origin software. 
 
2.2.3  Intrinsic Tryptophan (Trp) Fluorescence Spectroscopy 
Using a Photon Technology International (PTI) spectrofluorometer 
(Lawrenceville, NJ), samples were excited at 295 nm (>95% Trp emission), and the 
resulting fluorescence emission was collected from 300 to 400 nm.  Spectra were 
obtained following a 5 min thermal equilibration period every 2.5 oC from 10 to 80 oC.  
Data were acquired in triplicate and subsequently averaged.  The resulting spectra were 
imported into Microcal Origin (version 7.0) where the buffer background was subtracted, 
and the spectra were smoothed using an 11-point second order Savitsky-Golay 
polynomial.  The wavelength of the emission maximum was determined using the first 
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derivative of the smoothed data, and the corresponding peak position and intensity were 
plotted with respect to temperature.  Additionally, the fluorescence intensity at 295 nm 
was also recorded as a measure of light scattering. 
 
2.2.4  ANS Binding 
Apolar sites characteristically buried in the core of proteins often become more 
accessible with structural alterations.  Such changes were probed through the use of the 
fluorescent dye 8-Anilino-1-napthalene sulfonate (ANS), although the presence of the 
negative charge on the dye always requires qualification concerning potential 
electrostatic components of binding [32].   An optimized 10-fold molar excess of ANS to 
protein (0.2 mg/mL) was prepared and excited at 375 nm.  Emission spectra were 
collected from 400-600 nm every 2.5 oC, from 10-80 oC following a 5 min thermal 
equilibration.  Prior to data analysis, a spectrum of the negligible ANS emission in the 
absence of protein was subtracted from the corresponding spectrum at the same 
temperature and pH.  The intensity of fluorescence emission at 485 nm was plotted as a 
function of temperature to assess changes in ANS binding upon thermal perturbation. 
 
2.2.5  Far-UV Circular Dichroism Spectroscopy 
The secondary structure of the three proteins was characterized over the pH range 
of interest using a Jasco J-720 spectropolarimeter equipped with a six position sample 
holder.  Temperature was regulated with a Peltier control device (Easton, MD).   Far-uv 
spectra were initially recorded at 10 oC from 260 to 190 nm in a 0.1 cm path length cell.  
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Subsequently, samples were heated from 10-80 oC and monitored at 222 nm following a 
five min. thermal equilibration period at each 0.5 oC interval.  Using the instrument 
software, the resulting data were converted to molar ellipticity as a function of 
temperature.  Midpoints of thermal transition were determined using Microcal Origin 
sigmoidal fit graphing tools. 
 
2.2.6  Analysis of Thermal Unfolding Data 
Thermodynamic unfolding values were calculated using molar ellipticity thermal 
unfolding curves at the various pH values.  Assuming a two state model, a sigmoidal 
Van’t Hoff plot of the fraction unfolded with respect to temperature was generated using 
equation 1 shown below.  The equilibrium constant at each data point was then 
determined from the relationship shown in equation 2, and subsequently used in equation 
3 to arrive at an experimentally determined value for the Gibbs free energy (ΔGU).  A 
Gibbs free energy plot was generated and fit to a linear equation (4) to obtain the entropic 
and enthalpic contributions to the thermal unfolding event at each pH. 
 
fU = ΘN-Θ/ΘN-ΘU      (1) 
KU = [U]/[N] = fU /1- fU   (2) 
ΔGU = -RTlnKU    (3) 
ΔGU = ΔHU - TΔSU    (4) 
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2.2.7  Empirical Phase Diagrams 
An empirical phase diagram was constructed to combine data acquired using the 
multiple spectroscopic techniques described above [20-27].  This permits a 
comprehensive comparison of the response of each protein to temperature and pH in 
terms of secondary and tertiary structure change as well as any association/dissociation 
events present.  Each plot was generated using MatLab software, employing combined 
data from each technique to create a multi-component vector at each temperature-pH 
condition.  Together, the vectors form an n x n density matrix where n represents the 
number of variables used in the data set.  Subsequently, n sets of eigenvalues and 
eigenvectors are derived from the data and normalized, and the three with the greatest 
magnitude are assigned to arbitrarily selected red, blue or green color.  Regions of the 
diagram with similar color represent related physical states of the protein, and therefore 
permit the identification of “apparent” phase boundaries which represent structural or 
size changes in the protein.  Note that these diagrams are not the commonly encountered 
thermodynamic phase diagrams and thus, no equilibrium is implied between the 
empirically defined phases.  Further discussion of this approach is presented elsewhere 
[20-27, 33]. 
 
2.3  Results 
 
2.3.1  High Resolution UV Absorbance Spectroscopy 
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The second derivative UV absorbance spectra of MxiHΔ5, BsaLΔ5 and PrgIΔ5 were 
de-convoluted to display the individual contributions from the three aromatic residues, 
Phe, Tyr and Trp.  Six negative peaks were observed, and at 10 oC their approximate 
wavelengths were:  253 nm (Phe), 259 nm (Phe), 270 nm (Phe/Tyr), 277 (Tyr), 284 nm 
(Tyr/Trp), and 290 nm (Trp) [24].  Information regarding structural changes in the 
protein’s tertiary structure was obtained by monitoring shifts in peak position with 
varying pH and increasing temperature.  This method serves as a sensitive 
conformational probe given the unique distribution of the aromatic amino acids 
throughout the core and terminal domains of the proteins.  For example, the sole Trp 
residue found in each of the three proteins is located in its N terminal region.  As a result, 
changes seen in the Trp specific absorbance can be primarily attributed to changes in the 
N terminal region of the protein.  Similarly, the mutant proteins contain only one Phe 
residue, with the exception of PrgI, which is positioned in the N terminal alpha helix.   
Alternatively, multiple Tyr residues are dispersed throughout the alpha helix core, and 
therefore do not permit such unambiguous interpretations. 
Phe spectral peaks, which demonstrate absorption maxima at approximately 253 
(data not shown) and 259 nm (Figure 2.3), experienced 1-2 nm red shifts in peak position 
with increasing temperature.  Phe residues are typically found within the apolar core of 
proteins, and are consequently the last to undergo a change in environment as structure is 
altered.  For all three proteins, it appears that the shift in Phe peak position at pH 3-6 is 
relatively linear and continuous, and therefore probably reflects the intrinsic effect of 
temperature on the aromatic side chains 
 37 
 
 
Figure 2.3 Effect of temperature on MxiHΔ5 (A), BsaLΔ5 (B) and PrgIΔ5 (C) as 
observed by a shift in second derivative near-UV absorbance peak position representing 
the contribution made by Phe residues at pH 3.0 (red), 4.0 (green), 5.0 (blue), 6.0 
(yellow), 7.0 (purple), and 8.0 (black). 
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 [24].  At pH 7 and 8, however, the shift becomes increasingly nonlinear in nature, and 
therefore presumably represents alterations in structure induced by thermal perturbation. 
The Tyr peak at 277 nm exhibits a blue shift of approximately 1 nm over the 
temperature ramp, and demonstrates a distinct sigmoidal response with a clear transition 
in all cases (Figure 2.3a, d, g).  As mentioned above, the mutant proteins contain several 
Tyr residues in the alpha helical regions, and consequently the resultant data are a 
summation of polarity changes in numerous micro-environments throughout the proteins.  
For each of the three proteins studied, the midpoint of the thermal transition (Tm) varied 
with respect to pH, and the pH at which the highest Tm was seen varied among the three 
proteins.  For all three proteins, however, the lowest Tm occurred at pH 3.  With respect 
to MxiH Δ5, peak shifts at pH 3 and 4 appear to be slightly blue shifted compared to the 
other pH conditions.  Additionally, it appears that the onset temperature defining the 
transition occurs at slightly lower temperatures than at the higher pH conditions.  In the 
case of BsaLΔ5 and PrgIΔ5, this trend was not observed. 
The negative peak seen near 290 nm at 10 oC which represents contributions 
solely from the single Trp residue did not display any significant shifts in its absorption 
maximum peak position for any of the three proteins indicating that the local 
environment of this particular residue did not undergo major alterations upon thermal 
stress or changes in pH, presumably due to its surface exposure in the truncated version 
(data not shown) [8, 11, 34].  The remaining two peaks represent a combination of 
aromatic contributions, (Phe/Tyr and Tyr/Trp at approximately 253 and 270 nm at 10 oC, 
respectively), both of which display blue shifts of approximately 1 nm with transition  
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Figure 2.4 Effect of temperature on MxiHΔ5 (A-C), BsaLΔ5 (D-F) and PrgIΔ5 (G-I) as 
observed by multiple spectroscopic techniques at pH 3.0 (red), 4.0 (green), 5.0 (blue), 6.0 
(yellow), 7.0 (purple), and 8.0 (black).  (A, D, G)  Shift in second derivative near-UV 
absorbance peak position representing the contribution made by the three Tyr residues as 
a function of temperature.  (B, E, H)  ANS fluorescence intensity as a function of 
temperature.  (C, F, I)  Molar ellipticity at 222 nm as a function of temperature. 
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midpoints of roughly 40 oC (data not shown).  Based on the previously described data of 
the individual contributions of each type of aromatic residue, the changes seen in the 
combination peaks presumably reflect a dominating contribution of the Tyr residues. 
The optical density at 350 nm was concurrently monitored to evaluate the 
propensity of the proteins to associate upon thermal stress.  In the case of all three 
proteins, no significant change was seen as the temperature was increased (data not 
shown).  This suggests that the observed thermal transitions do not result in the formation 
of large insoluble aggregates, and is consistent with previous findings regarding the 
reversible nature of MxiHΔ5 and PrgIΔ5 thermal transitions [28]. 
 
2.3.2  Intrinsic Trp Fluorescence Spectroscopy 
The single Trp residue in each of the three proteins was used as an intrinsic 
fluorescent probe to monitor changes in protein tertiary structure under varying pH and 
temperature conditions.  Each of the three monomeric proteins exhibited a maximum 
emission wavelength between 345 and 350 nm at 10 oC at all six pH values which 
remained unchanged with increasing temperature (data not shown).  This observation 
suggests that the indole ring of the Trp sidechain is extensively exposed to the solvent at 
10 oC, and upon thermal perturbation does not experience a change in polarity in its local 
environment.  Furthermore, the intensity of the fluorescence at the maximum emission 
wavelength decreases in a curvi-linear manner for all three proteins at all six pH values 
suggestive of intrinsic temperature effects (data not shown).  The fluorescence intensity 
at 295 nm was also monitored during the thermal perturbation of the samples and used to 
 41 
monitor potential changes in oligomerization state.  Similar to the results observed while 
monitoring optical density upon thermal stress, no apparent increase was observed (data 
not shown).  This observation indicates that at the protein concentration studied here, 
association and/or aggregation of the monomeric proteins upon thermal stress over the 
pH range of 3-8 is not detectable. 
 
2.3.3  ANS Fluorescence Spectroscopy 
ANS was used as an extrinsic fluorescent probe to monitor changes in protein 
apolar binding sites upon increasing temperature and varying pH.  In general, the 
quantum yield of ANS increases upon binding to apolar regions.  As proteins partially 
unfold, the internally buried apolar groups become more exposed to the solvent, and 
consequently interaction with ANS often increases with subsequent enhancement of ANS 
emission.  For each of the three proteins, similar trends in intensity changes of ANS at 
each pH were observed.   Slight differences, however, were evident.  All three proteins 
appear to have the greatest apolar character at pH 3 and 10 oC, suggesting that they are 
somewhat structurally disrupted at low pH even at reduced temperatures. 
At 485 nm, the intensity of ANS fluorescence in the presence of MxiHΔ5 at pH 3 
and 4 exhibits a melting curve with a transition midpoint of approximately 50 oC (Figure 
2.3b).  A slight decrease in intensity with temperature probably due to intrinsic 
temperature effects is seen at pH 5 and 6, which both initiate at notably lower intensity at 
10 oC relative to the results at pH 3 and 4.  ANS spectra at pH 7 and 8 also exhibit similar 
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intensities, but do not display any significant alteration over the temperature range 
examined. 
In the case of BsaLΔ5, the ANS intensity at pH 3 decreases in a nearly linear 
manner until approximately 30 oC, at which point it continues to decrease but with a more 
positive slope (Figure 2.3e).  When the pH is increased to 4, a similar trend is again 
observed but with significantly lower intensity.  Subsequent increases in pH produce the 
same trend for each pH, differing only in the decreasing intensity with increasing pH. 
The fluorescence intensity at 485 nm of ANS in the presence of PrgIΔ5 at pH 3 
exhibits more commonly observed ANS behavior with a distinct transition onset 
temperature of approximately 40 oC, and midpoint at 50 oC (Figure 2.3h).  The same 
decreasing intensity with increasing temperature seen for BsaLΔ5, however, is exhibited 
by PrgI for the remaining pH conditions (4-7), since significantly less fluorescence 
intensity is observed with increasing pH and temperature.  At pH 8 and low temperatures, 
a slight increase in ANS fluoresce intensity is observed, which suggests an increase in 
ANS binding.  It should be emphasized that ANS binding may also be influenced by an 
electrostatic component.  The pI of each of the three proteins is 4.5, 4.8 and 4.8 for 
MxiH, PrgI and BsaL respectively, which suggests that the results seen at low pH could, 
in fact, be complicated by electrostatic interactions with the negatively charged dye. 
 
2.3.4  Far-UV Circular Dichroism Spectroscopy 
At each of the six pH values, all three proteins produced spectra displaying double 
minima at 208 and 222 nm consistent with a α-helical structure [28].  The thermal 
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stability of the secondary structure at varying pH values was evaluated by monitoring the 
molar ellipticity at 222 nm as a function of temperature.  All three proteins exhibited 
evidence of a major loss of secondary structure as implied by the large decrease in 
negative molar ellipticity with increasing temperature (Figure 2.3c, f, i).  The transition 
representing a change in secondary structure with temperature was broad but sigmoidal in 
all cases, and appeared to begin at temperatures as low as 10 oC.  The midpoint of the 
thermal transition (Tm) for each of the three proteins over the pH range studied varied 
from 35 +/- 0.5 to 50 +/- 1.1 oC, and at the concentrations examined, thermal transitions 
were >90 % reversible [30].  Data were not available below 200 nm due to interference 
from buffer components; therefore, no attempt was made to analyze the spectra further 
for secondary structure content. 
With respect to MxiHΔ5, pH 5 and 6 produced the greatest thermal stability (Tm 
values of 42.9 and 42.1 oC respectively).  In the case of BsaLΔ5, pH 4 and 5 resulted in 
the greatest thermal stability with Tm values of 50.8 and 50.1 oC, with a subsequent 
increase or decrease in pH again resulting in a notable decrease in the Tm.  PrgIΔ5 
displayed the greatest thermal stability at pH 3 and 4 (42.7 and 42.5 oC), with an increase 
in pH characterized by a significant decrease in thermal stability. 
 
2.3.5  Thermodynamics 
Given the reversible nature of the transitions observed using circular dichroism 
(Figure 2.5a), the thermodynamics of thermal unfolding of the three proteins were 
analyzed to obtain a more quantitative description of the conformational changes induced  
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Figure 2.5 (A) A circular dichroism spectrum prior to thermal unfolding is 
shown in black, while the grey line indicates the same sample following the thermal melt 
and re-cooling to 10 oC.  (B) Thermal melting curves acquired using circular dichroism 
are well fit by a two state transition model as shown by the solid grey line.  Plots shown 
in both (A) and (B) represent data acquired for MxiHΔ5 at pH 7, and are representative of 
trends observed for all three proteins at all pH values. 
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by both temperature and pH.  Despite the lack of highly cooperative character observed 
in the surprisingly gradual transitions (probably due to the flexible nature of the C and N 
termini observed by NMR and crystallography), the data were well fit by a 2-state model 
with r2 values exceeding 0.98 in all cases (Figure 2.5b).  The apparent Gibbs free energy 
of unfolding (ΔGu) obtained at 37 oC is found to vary in magnitude with respect to pH, 
but is, as expected, unfavorable (positive) for all three proteins across the pH range of 
interest (Figure 2.6b).  MxiHΔ5 displayed the lowest intrinsic stability at pH 3 (0.27 +/- 
0.02 KJ/mol) and the greatest at pH 6 (1.75 +/- 0.09 KJ/mol).   Similarly, PrgIΔ5 
demonstrated the greatest intrinsic stability at pH 5 (1.77 +/- 0.22 KJ/mol), and 
significantly decreased with both increases and decreases in pH.  BsaLΔ5 produced the 
most consistent values across the pH gradient, experiencing the least intrinsic stability at 
pH 4 (1.08 +/- 0.12 KJ/mol), and the greatest at pH 6 (1.59 +/- 0.07 KJ/mol).  As 
temperature increases above the physiological range, however, and approaches the 
various melting temperatures for each of the proteins, ΔGu decreases and becomes 
negative indicating thermal unfolding is a spontaneous process at higher temperatures.  
Further analysis of the thermodynamic parameters conducted at 37 oC reveals that the 
thermal unfolding of all three proteins over the pH range of 3-8 is enthalpically driven, 
with enthalpy (Figure 2.6c) and entropy (Figure 2.6d) contributions displaying significant 
pH dependence across the range of interest.  We emphasize caution in the use of these 
parameters, however, due to the unusual shape of the transition. 
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Figure 2.6 Summary of the midpoint of thermal unfolding (Tm) and thermodynamic 
parameter values for MxiHΔ5, BsaLΔ5 and PrgIΔ5.  (A)  Tm values as monitored by molar 
ellipticity at 222 nm for MxiHΔ5 (□ dashed line), BsaLΔ5 (○ dashed line) and PrgIΔ5 (Δ 
dashed line), as well as by uv-absorbance at 277nm (Tyr) for MxiHΔ5 (■ solid line), 
BsaLΔ5 (● solid line) and PrgIΔ5 (▲ solid line).  (B)  Values of ΔGunfolding at 37 oC for 
MxiHΔ5 (■), BsaLΔ5 (●) and PrgIΔ5 (▲).  (C) Values of ΔHunfolding at 37 oC for MxiHΔ5 
(■), BsaLΔ5 (●) and PrgIΔ5 (▲).  (D)  Values of ΔSunfolding at 37 oC for MxiHΔ5 (■), 
BsaLΔ5 (●) and PrgIΔ5 (▲). 
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2.3.6  Empirical Phase Diagrams 
To summarize the effect of pH and temperature on the truncated monomeric 
needle proteins, an empirical phase diagram (EPD) was constructed (Figures 2.7A-C).  
The components of the vectors that comprise each T, pH point are based on the far-UV 
circular dichroism, extrinsic (ANS) fluorescence and the high resolution UV absorbance 
spectroscopy data described above.  We emphasize that these are not necessarily 
equilibrium (thermodynamic) phase diagrams (the reversibility of all pH induced changes 
has not been established), but are an empirical representation of changes in structure as a 
function of environmental variables.  In this case, regions of similar color indicate 
physically similar conformational states of the protein.  Thus, EPDs incorporate data 
sensitive to multiple aspects of protein secondary and tertiary structure.  Note that the 
assignment of color is arbitrary.  Therefore, similar colors between the three individual 
EPDs are not meant to imply similar conformational states.  One marked similarity 
among the EPDs for each of the three proteins is the presence of a structurally altered 
state at low pH (3) and low temperatures.  While the temperatures at which abrupt color 
changes for each protein at each pH vary, it appears that a major change in physical state 
occurs in the temperature range of 35-40 oC for all three proteins.  With the exception of 
the molar ellipticity temperature data, thermal transitions appear relatively minor for all 
three proteins.  The gradations in color seen over a fairly wide temperature range for all 
proteins suggests the presence of transient intermediate states despite the fact that the 
thermal unfolding data is well fit by a two state model. 
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Figure 2.7 Empirical phase diagrams (EPDs) for (A) MxiHΔ5, (B) BsaLΔ5 and (C) 
PrgIΔ5 generated using Tyr second derivative near-UV absorbance peak positions, ANS 
fluorescence intensity, and CD molar ellipticity at 222 nm data all as a function of 
temperature and pH.
C. 
 B. 
A
. 
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2.4  Discussion 
The results presented here describe a comprehensive set of thermal and pH 
perturbation studies of the MxiHΔ5, BsaLΔ5 and PrgIΔ5 monomeric TTSS needle proteins.  
The truncated versions of interest contained a His6 tag for purification purposes, but 
previous results indicate the tag does not inhibit the formation of functional needles.  
Thus it is not expected to interfere with the conformational and thermal perturbation 
studies presented here [35].  It must be acknowledged, however, that it is possible that the 
presence of the His6 tag may induce a degree of instability in the monomeric variants. 
Circular dichroism spectroscopy data is consistent with the NMR solution and 
crystal structure data recently obtained for BsaLΔ5, PrgIΔ5 and MxiHΔ5 which 
demonstrated that these proteins’ secondary structures consist of two anti-parallel alpha 
helices flanked by unstructured N and C termini [8, 11, 34].  Thus, the CD spectra 
indicate that the secondary structure of all three proteins is largely alpha helical, but 
additionally, remarkably thermally unstable.  Thermal transitions indicating a major loss 
in secondary structure appear to begin at temperatures as low as 10 oC, with midpoints of 
thermal unfolding in the range of 35 +/- 0.5 to 50 +/- 1.1 oC for all three proteins over the 
pH range of 3-8.  At low temperatures, PrgIΔ5 does not appear to exhibit variations in 
secondary structure with respect to pH, while BsaLΔ5 and MxiHΔ5 display small 
differences in molar ellipticity from one pH to another.  Circular dichroism experiments 
were also conducted at a constant salt concentration (ionic strength) of 0.15 where it was 
observed that transitions seen in the temperature and pH studies described here were 
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shifted to lower temperatures, but displayed very similar pH dependence (data not 
shown).  Furthermore, fluorescence data obtained at constant salt concentration also 
revealed trends analogous to those presented here. 
Observations using both fluorescence and absorbance spectroscopy concerning 
the tertiary structure of the proteins confirm that the local environment surrounding the 
single Trp residue found in the N terminal region of each protein is relatively polar at low 
temperatures as well as across the entire pH region examined.  This is consistent with the 
N terminus being unstructured as observed in the previously mentioned NMR and X-Ray 
based structures for BsaLΔ5 and MxiHΔ5 [8, 11, 34].  Phe absorbance measurements as a 
function of temperature and pH also provide little evidence for major conformational 
changes, although a careful inspection of the data for all three proteins does find a subtle 
deviation from the curvilinear wavelength maximum versus temperature behavior above 
40 oC at higher pH (>6).  Thus, some subtle disruption of the protein’s tertiary structure 
does appear to be occurring.  Additionally, the effect of temperature on the multiple Tyr 
residues dispersed throughout the structure of each of the proteins show clear transitions 
indicating the occurrence of a thermal event. 
A global presentation of the spectroscopic data for each truncated protein was 
presented in the form of EPDs to better illustrate the combined effects of temperature and 
pH on both the secondary and tertiary structure of the proteins.  The most striking 
observation for each of the three proteins is their low thermal stability over the entire pH 
range examined.  For all three proteins, pH 3 appears to induce a thermally altered 
conformational state at temperatures as low as 10 oC, which correlates with the increased 
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ANS fluorescence observed under those conditions, and is indicative of solvent 
accessibility within the apolar protein core.  Based on the EPDs, it appears that MxiHΔ5 
displays the greatest thermal stability at pH 6, BsaLΔ5 at pH 5 and PrgIΔ5 at pH 4. 
Evaluation of the intrinsic conformational stability of MxiHΔ5, BsaLΔ5 and PrgIΔ5 
with respect to thermal unfolding as monitored by circular dichroism provides 
information concerning the driving force behind the formation of each protein’s native 
structure.  At physiological temperatures (37 oC), the free energy difference between the 
folded and unfolded state of each protein varies with pH, but is positive in all cases and 
ranges from approximately 0.3 to 1.8 KJ/mol.  It has been reported that for a globular 
protein of this size, a more common ΔGU value under physiological conditions would be 
20 to 60 KJ/mol [36].  It is possible that this very low free energy difference may be a 
reflection of the biological significance of the unfolded or molten globule like states 
displayed by the needle proteins under physiological like conditions.  A lack of favorable 
changes in free energies is also observed, and together with the low free energy change 
suggests that the proteins lack a substantial apolar interior. 
Comparison of the transition midpoint temperatures obtained using CD and Tyr 
UV-absorbance spectroscopy indicates that upon thermal stress, all three proteins may 
exist in one or more intermediate conformational states in which their tertiary structure 
has been compromised, but secondary structure elements remain (Figure 2.6a).  This 
partially structured or molten globule like state persists in some cases over as wide a 
range as 12 oC, but varies in duration across the pH range for each protein.  It is 
interesting to note that for each protein, the bulk of the transition temperatures acquired 
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from the CD and UV absorbance thermal melting curves follow similar trends across the 
pH range of interest.  For example, BsaLΔ5 displays the lowest thermal stability at pH 3 
with respect to both secondary and tertiary structure relative to the higher pH values.  As 
the pH is increased to 4, however, the midpoints representing the corresponding 
transitions both significantly increase.  Further increases in pH (5-8) are characterized by 
a continuing decrease in transition midpoints as detected by both methods.  Thus, while 
the absolute transition temperatures representing the thermal stability of the secondary 
and tertiary structural elements of BsaLΔ5 at each pH differ significantly, their trend 
across the pH range investigated here appears to be the same.  The same is seen for PrgIΔ5 
and MxiHΔ5.   A transient nature for the unfolding intermediates is suggested by the fact 
that the data are still well fit by a two state model. 
A role for partially unfolded states of proteins in their transport across cellular 
barriers has frequently been suggested.  Such studies have argued that these nonnative 
states can be induced by membrane surfaces, with the induction of structural disruption 
attributable to two phenomena [37].  The first involves the presence of the negative 
electrostatic potential found on most membrane surfaces [38]. This attracts protons to 
exterior negative charges, and consequently the pH near the surface may drop by up to 
two pH units [38].  Such an effect is thought to lower the pH in a region up to 15 Å from 
the membrane surface [39, 40].  A second phenomenon involves increased electrostatic 
repulsion of negative charges resulting from a reduced dielectric constant near the 
membrane surface [39].  This could also lead to protein structure alterations.  Although 
this model has been more commonly applied to eukaryotic cell surfaces, it appears 
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reasonable in this case given the presence of phosphatidylglycerol, a negatively charged 
lipid, on the cytoplasmic surface of the inner bacterial membrane of gram negative 
bacteria [41]. 
The pH at which each protein experiences its greatest thermal stability with 
respect to both secondary and tertiary structure differs despite their structural and 
functional similarities.  The dependence of pH has been previously noted in the S. 
typhimurium system where needles dissociated upon an increase in pH from 8.0 to 10.5 
[42].  It is possible that this variation in stability may reflect a functional aspect of the 
monomeric proteins’ behavior.  Due to the size difference between the inner pore of the 
needle and fully folded proteins, it seems clear that the needle subunits must be secreted 
in a partially or completely unfolded state to reach the distal tip of the needle for 
assembly.  Additionally, while both Salmonella and Shigella access host epithelium via 
specialized M cells, Salmonella gains access to a host through the small intestine, while 
Shigella uses a structurally and functionally conserved TTSS to invade in the large 
intestine [43].  The variation in pH within different segments of the intestinal tract in 
coordination with the low thermal stability of the needle subunits at critical pH values 
could thus be involved in dictating the formation of the external needle structures. 
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Table 2.1 Summary of the midpoint of thermal unfolding (Tm) and thermodynamic 
parameter values for MxiHΔ5, BsaLΔ5 and PrgIΔ5.  Thermal data in oC and thermodynamic 
data in J/mol, J/mol and J/K*mol for ΔG unfolding, ΔH unfolding and ΔS unfolding  respectively. 
 
 
 
 
 
       Tm for 2o (CD)    Tm for 3o (Tyr)         ΔGunfolding             ΔHunfolding             ΔSunfolding 
            
 pH Average St.Dev. Average St.Dev. Average St.Dev. Average St.Dev. Average St.Dev. 
MxiH 3 35.5 0.5 30.5 0.6 271 15 8.58E+04 5.99E+03 277.0 20 
 4 38.8 0.8 34.9 0.6 893 43 9.38E+04 3.62E+03 300.1 12 
 5 42.9 0.3 36.3 2.2 1732 24 1.03E+05 8.12E+03 330.7 27 
 6 42.1 0.3 36.6 2.7 1755 89 8.75E+04 5.29E+03 277.9 18 
 7 40.3 0.2 37.8 1.1 1515 37 1.08E+05 9.36E+03 346.1 31 
 8 39.9 0.3 34.3 1.1 1363 57 1.11E+05 5.60E+03 355.9 19 
             
BsaL 3 41.7 0.3 30.7 2.2 1225 76 8.25E+04 6.75E+03 263.0 22 
 4 50.8 1.1 46.3 2.7 1082 121 7.89E+04 6.24E+03 251.2 20 
 5 50.1 1.6 40.8 1.7 1481 42 9.21E+04 9.64E+03 296.8 30 
 6 46.3 0.5 38.7 2.6 1584 184 9.20E+04 1.39E+04 295.6 46 
 7 44.8 0.1 38.4 3.3 1569 71 9.64E+04 1.59E+04 310.8 51 
 8 44.7 0.1 38.9 1.9 1457 306 8.34E+04 4.97E+03 269.7 16 
             
PrgI 3 42.7 0.6 30.5 0.9 1093 88 7.60E+04 5.47E+03 242.5 18 
 4 42.5 0.6 32.9 2.9 1522 114 6.17E+04 2.05E+03 194.9 6 
 5 40.2 0.8 31.6 0.5 1766 221 6.54E+04 3.32E+03 206.1 11 
 6 39.9 0.2 33.3 1.9 745 51 7.55E+04 3.35E+03 238.7 11 
 7 38.7 0.6 28.7 2.1 780 59 8.37E+04 8.49E+03 264.9 27 
 8 38.7 0.4 28.9 2.7 667 120 8.03E+04 1.07E+04 258.0 31 
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3.1  Introduction 
Shigella flexneri, Salmonella typhimurium and Burkholderia pseudomallei are 
three pathogens responsible for an extensive number of potentially preventable disease 
cases.  For example, Shigella is one of the leading causes of infant mortality in 
developing countries, and is responsible for endemic infection levels worldwide which 
involve more than 165 million people each year [1].  Salmonella is best known for its 
high-profile outbreaks in the developed world and is associated worldwide with more 
than 200 million cases every year [2-4].  Burkholderia is endemic to tropical regions, and 
is listed as a Category B Bioterrorism Agent by the CDC due to its severe course of 
action, potential for aerosol delivery and worldwide availability [5].  Perhaps the most 
disturbing fact is the lack of licensed vaccines for prevention of infection by all three of 
these opportunistic pathogens and their increasing resistance to antibiotic treatment [6-9].  
The need for further vaccine development in this area is widely recognized and work 
shown here is intended to support that effort.      
These extremely virulent, opportunistic pathogens are most dangerous to young, 
elderly and otherwise immuno-compromised individuals.  Shigella and Salmonella are 
most commonly transmitted through contaminated food or water via the fecal oral route, 
thus countries with limited sanitation systems are often the most affected.  Symptoms of 
Shigellosis and Salmonellosis include fever, vomiting and dysentery.  Burkholderia 
differs in that infection is typically acquired from bacteria found in the soil and water 
through open sores or lesions [10].  Person-to-person spreading, however, has been 
documented [5].  Symptoms of mellioidosis vary widely depending on the severity of the 
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infection.  In some cases the bacteria will lie dormant for years, while in more extreme 
cases, acute localized, pulmonary, bloodstream and chronic infections are possible [10].   
Each of these pathogens relies upon a Type Three Secretion System (TTSS) for 
virulence.  This system, commonly referred to as a molecular ‘injectisome’, is composed 
of more than 20 proteins which assemble to form basal and extracellular components 
[11].  This macromolecular conduit allows the bacteria direct physical contact with a host 
cell and is responsible for the transport of effector proteins from the bacterial cytoplasm 
directly into the host cell where they subvert normal cell function [12, 13].  The surface 
exposed ‘needle’ portion of the structure is composed of approximately 120 copies of a 
monomeric subunit arranged in a hollow helical array with an inner diameter of 
approximately 2.0-3.0 nm [12-17].  This appendage is required for virulence and is 
intimately involved in the initial stages of an infection.  Therefore we have explored the 
use of these surface exposed proteins as potential vaccine antigens [18, 19].   
The vaccine antigens studied here are the monomeric subunits of the oligomerized 
needle appendage from each bacterial system.  These small (~10 kDa), acidic (pI <5) 
proteins are characterized by distinct patches of both positive and negative surface 
charge, which likely contribute to their intrinsic polymerization [20].  When 
recombinantly expressed, their propensity to oligomerize results in a viscous solution of 
highly associated products; however, it is possible to attain soluble monomer protein if 5 
residues from the C terminus are deleted [21].  The resultant recombinant mutant proteins 
MxiH Δ5, PrgI Δ5 and BsaL Δ5 from the gram-negative bacteria Shigella flexneri, 
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Salmonella typhimurium and Burkholderia pseudomallei respectively have been shown to 
retain native structure [22]. 
Previously, we characterized the solution stability of the mutant monomeric 
needle antigens, and found them to be pH sensitive, thermally labile proteins with 
reversible transitions and molten globule-like behavior in the physiological temperature 
range [23].  Additionally, initial immunogenicity studies have shown MxiH Δ5 and PrgI Δ5 
to be antigenic in a murine model (submitted).  Here we describe pre-formulation studies 
of these vaccine candidates.  It should be emphasized that the intention of this work is not 
to propose clinical formulations, but rather to examine aspects of potential future 
formulations which may be useful for further development of these and other related 
vaccines based on the needle proteins. 
 
3.2 Materials and Methods 
 
3.2.1  Materials 
C terminal truncated proteins were expressed in E. coli with a C terminal His6 tag 
as described previously [17, 21, 22].  Affinity purification was performed using nickel 
chelation chemistry, and the samples were dialyzed against isotonic pH 6 citrate 
phosphate buffer and stored at -80 oC until use.  Alhydrogel® (2%) and Adjuphos® were 
acquired from E.M. Sergeant Pulp and Co., Inc. (Clifton, NJ). 
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3.2.2  Screening for Excipients 
Potential excipients were screened for stabilizing effects using far-UV circular 
dichroism spectroscopy.  Secondary structure was used as the stability indicating 
parameter in this case because of the lack of other temperature sensitive signals (ie: Trp 
fluorescence, static light scattering) exhibited by these proteins [23].  Thermal melts were 
conducted using a Jasco J-720 spectropolarimeter equipped with a six position sample 
holder and a Peltier temperature control device (Easton, MD).   Initially, individual far-
UV CD spectra were recorded for each of 6 samples at 10 oC from 260 to 190 nm in a 0.1 
cm path length cell.  The cell holder temperature was then increased from 10 to 85 oC in 
increments of 0.5 oC, and at each temperature step the cell holder was incubated for 5 min 
to ensure thermal equilibration of the samples before a scan was obtained.  For each 
thermal melt, a control protein sample containing 0.25 mg/mL protein in isotonic citrate 
phosphate buffer at pH 6.0 was run simultaneously with 5 samples containing test 
compounds at the indicated concentrations.  Spectra of the compounds alone were also 
collected and subtracted from the protein spectra when necessary.  Using the instrument 
software, the resulting data were converted to molar ellipticity as a function of 
temperature.  Midpoints of thermal transition (Tm) were determined using Microcal 
Origin® sigmoidal fit graphing tools.      
 
3.2.3  Adsorption Isotherms 
 Protein was dialyzed into isotonic 10 mM Histidine buffer at pH 6 overnight at 4 
oC using 3,500 MWCO Slide-A-Lyzer Dialysis Cassettes (Thermo Scientific, Rockford, 
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IL).  Upon completion, the protein concentration was determined by UV absorbance 
spectroscopy using an Agilent 8453 UV/Vis spectrophotometer equipped with diode 
array detector (Agilent Technologies, Santa Clara, CA).  Extinction coefficients of 9,970, 
11,460, and 12,950 M-1 cm-1 at 280 nm were used for MxiH Δ5, PrgI Δ5 and BsaL Δ5 
respectively [23].  Protein was then adsorbed to aluminum hydroxide by combining a pre-
determined volume of aluminum hydroxide stock, protein stock and histidine buffer to 
produce a range of protein concentrations (0-1.25 mg/mL) and a constant aluminum 
concentration (0.5 mg/mL), and allowing it to rotate end-over-end at 4 oC for 1 hour.  
Samples were then centrifuged at 14,000 g for 30 sec, and the resulting supernatant was 
removed and assayed for protein content by UV absorbance spectroscopy.  The amount 
of protein adsorbed was determined by subtracting the amount found in the supernatant 
from the original amount added.   
 
3.2.4  Adsorption Mechanism 
‘Elution’ solutions were prepared in isotonic pH 6 histidine buffer using ACS 
grade reagents and were not pH adjusted. The adsorption protocol described above was 
used to prepare several 1.5 mL samples containing 0.2 mg/mL protein per 0.5 mg/mL 
aluminum, a ratio at which > 95% of the protein is adsorbed.  The samples were then 
centrifuged for 2 min at 3,000 g to pellet the aluminum-protein complex, and the 
resulting supernatant was removed.  A control sample was prepared by adding 1 mL of 
isotonic 10 mM Histidine buffer at pH 6 to an aluminum-protein pellet.  In the same way, 
1 mL of a previously prepared ‘elution’ solution was added to each aluminum-protein 
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pellet containing vial.  All vials were then rotated end-over-end at 4 oC for 48 hours.  The 
samples were then once again centrifuged, and the supernatant of each evaluated for 
protein content. 
 
3.2.5  ELISA 
A standard Enzyme Linked Immunosorbent Assay (ELISA) was used to evaluate 
the stability of the adsorbed PrgI Δ5 vaccine.  Solution PrgIΔ5 and incubated aluminum 
adsorbed samples were plated (100 µL) onto Nunc-Immuno™ MediSorp™ (Nalge Nunc 
International, Wiesbaden, Germany) 96-well plates at 10 µg/mL in carbonate buffer (pH 
9.6) overnight at 4 oC.  Plates were blocked with Superblock per product instructions.  A 
1:10,000 dilution of Anti-PrgIΔ5 IgG was prepared in Superblock and allowed to incubate 
on the plate for 2 hours at RT.  The plates were then washed 4 times using a 0.85% 
Sodium Chloride solution.  HRP-conjugated Goat anti Mouse Monoclonal Antibody 
(Sigma, St. Louis, MO) was diluted 1:500 in blocking buffer, plated (100 µL) and 
incubated for 1 hour at RT.  The plates were then washed as above, and 3,3’5,5’-
TetraMethylBenzidine (TMB) substrate (100 µL) (Sigma, St. Louis, MO) was added.  
After 30 minutes at RT, 2 M HCl (100 µL) was added to quench the reaction and plates 
were read using a SpectraMax M5 plate reader (Molecular Devices, Sunnyvale, CA) at 
450 nm.  Statistical significance (p ≤ 0.05) was evaluated using a Student’s t-test in 
Microsoft Excel.   
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3.2.6  Capillary liquid chromatography-mass spectrometry analysis and protein mapping  
A 0.1 mg/mL trypsin solution was prepared by dissolving 5.2 mg of trypsin in 52 
mL of 0.05 M Ammonium Bicarbonate buffer at pH 6.6.  Protein was exposed to the 
trypsin solution at a 1:200 concentration ratio, and incubated at 37 oC for > 1 hour to 
permit adequate digestion.  Samples were introduced into an LTQ-FT Ultra Hybrid Mass 
Spectrometer (ThermoFinnigan) via capillary liquid chromatography as described [110].  
A data-dependant acquisition method was used for setting up the experiments. The five 
most intensive precursor ions in a survey MS1 mass spectrum acquired in the Fourier 
transform-ion cyclotron resonance over a mass range of 300–2000 m/z were selected and 
sequentially fragmented for MS2 analysis in the linear ion trap by collision-induced 
dissociation.  Experimental raw files were processed by TurboSequest batch search using 
BioWorks 3.2 software.  All text files generated by BioWorks 3.2 for every MS2 
fragmentation spectrum were combined within each experiment using an in-house written 
Perl script. The resulted files were submitted for peptide/protein identification to Mascot 
(v2.2, Matrix Science) database-searching program.  Parameters set during the searches 
were as follows: custom protein database, a peptide mass tolerance of 2.2 u to account for 
higher isotopes of large peptides and MS/MS tolerance of 0.6 Da, semi-trypsin specificity 
with up to two missed cleavages.  Variable modification was set to consider oxidation on 
methionine residues. Sequest and Mascot results were imported into Scaffold 2.2.03 
software (Proteome Software Inc.) for analyzing with X!Tandem search algorithm and 
statistical validation of peptide/protein identities.  Peptides validated by Scaffold at a 
confidence level of 50% and greater were taken to calculate protein coverage.  
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Identification of peptides at a confidence level of less than 50% was considered positive 
if their corresponding m/z value from the survey MS1 scans were found to be within 10 
ppm mass tolerance.  
 
3.3 Results 
 
3.3.1  Screening for Excipients 
 A panel of Generally Regarded as Safe (GRAS) compounds was screened for 
potential stabilizing effects on the secondary structure of all three recombinant proteins 
using temperature dependent circular dichroism spectroscopy.  As shown in Figure 3.1, 
MxiH Δ5 and PrgI Δ5 displayed broad yet distinctly sigmoidal transitions with midpoints of 
thermal melting (Tm) of 40.6 +/- 0.2 and 34.8 +/- 0.5 oC respectively.  The melting curve 
for BsaL Δ5 did not display sigmoidal behavior and as a result no thermal midpoint could 
be assigned.  The difference observed in the melting curves may be attributed to the 
absence of a critical salt bridge in BsaL Δ5 which is present in both MxiH Δ5 and PrgI Δ5 
[20].  For the purposes of excipient selection, we used changes in Tm as a quantitative 
measure of potential excipient effects. 
For both MxiH Δ5 and PrgI Δ5, stabilization, as represented by an increase in Tm, 
was observed in the presence of polyols and carbohydrates including glycerol, sorbitol, 
dextrose, trehalose, and sucrose.  As shown in Figure 3.2, greater stabilization was, for 
the most part, a function of increased excipient concentration.  Although it was not  
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Figure 3.1 Circular dichroism thermal melting curves for each MxiH Δ5 (____), PrgI Δ5 
(…..) and BsaL Δ5 (---) at 0.2 mg/mL in isotonic 10 mM Histidine buffer at pH 6.0. 
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Figure 3.2 Changes in Tm (oC) as measured by circular dichroism spectroscopy for 
MxiHΔ5 (▓) and PrgIΔ5 (░). 
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possible to confirm with Tm values, visual comparison of the BsaLΔ5 melting curves 
showed similar stabilization trends (data not shown).  Combinations of excipients were 
also screened using circular dichroism spectroscopy (data not shown).  Shown in Figure 
3.3 are the thermal melting curves for both MxiH Δ5 and PrgI Δ5 in the presence and 
absence of 10% Sucrose and 5% Dextrose, an excipient combination which was 
identified as optimal for all three proteins.  In both cases, approximately 4 oC of 
additional thermal stabilization was gained in the presence of 10% Sucrose and 5% 
Dextrose (MxiH Δ5, 40.4 to 44.4 oC and PrgI Δ5, 35.7 to 39.3 oC). 
 
3.3.2  Adsorption Isotherms 
The three proteins studied in this work are all quite acidic, with iso-electric points 
in the region of 4.5-5.0.  The two most commonly used FDA approved aluminum salt 
adjuvants are aluminum hydroxide, which is positively charged at neutral pH and has a 
point of zero charge (PZC) of 11, and aluminum phosphate, which is negatively charged 
at neutral pH and has a PZC of approximately 5-7 [25].  As one would expect, minimal 
adsorption of the needle proteins occurs in the presence of aluminum phosphate (data not 
shown), while substantial interaction was observed with aluminum hydroxide.  This 
phenomenon is presumably due to the electrostatic repulsive forces present between the 
aluminum phosphate and the protein at neutral pH, and the electrostatic attractive forces 
present on aluminum hydroxide and the proteins. As shown in Figure 3.4, the three 
proteins display similar adsorption isotherms with high levels of protein loading.  When  
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Figure 3.3 Circular dichroism thermal melting curves for (A) MxiHΔ5 and (B) PrgIΔ5 
at 222 nm in the presence (-) and absence (-) of 10% Sucrose and 5% Dextrose.   
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Figure 3.4 Adsorption isotherms for MxiH Δ5 (A), PrgI Δ5 (B) and BsaL Δ5 (C) with 
0.5 mg/mL aluminum in isotonic 10 mM histidine buffer at pH 6. 
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the data were plotted according to the Langmuir equation [26], straight lines with R2 
values in the range of 0.984 to 0.999 were obtained.  The adsorptive capacities were  
calculated to be 1.56, 1.72 and 1.62 mg/mg aluminum for PrgI Δ5, BsaL Δ5 and MxiH Δ5 
respectively.   
 
3.3.3  Adsorption Mechanism 
To investigate the forces responsible for adsorption of the needle proteins to 
aluminum hydroxide, a series of ‘elution’ solutions were prepared and adsorbed samples 
exposed to them.  Each solution is expected to primarily inhibit a specific type of protein-
adjuvant interaction.  Adsorbed samples were prepared as described above and 
supernatants were assayed for protein content prior to treatment.  In all cases, < 2% 
residual protein was observed indicating that approximately 98% of the protein was 
adsorbed prior to ‘elution’ treatment.  As shown in Table 3.1, when freshly adsorbed 
samples (< 24 h incubation) were treated nearly all the protein was desorbed from the 
surface in the presence of 1.0 M Guanidine Hydrochloride, 1.0 M Sodium Citrate, 1.0 M 
Monobasic Sodium Phosphate or 1.0 M Dibasic Sodium Phosphate.  Although the 
proteins have highly charged surfaces [20], they do not appear to interact with the 
adjuvant directly through electrostatic interactions since they are not eluted in the 
presence of up to 3.0 M Sodium Chloride.  If the adsorbed formulations were aged prior 
to analysis, the results differed significantly.  After 2 weeks of incubation at 4 oC, only 
the Sodium Phosphate and Sodium Citrate solutions were able to desorb the protein, and  
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Table 3.1 Protein (mg/mL) present in sample supernatant as assayed by UV 
absorbance spectroscopy following ‘elution’ treatment.  All samples originally contained 
0.2 mg/mL protein in the presence of 0.5 mg/mL aluminum.  Where a dash is present no 
sample was analyzed.  Error was estimated at approximately 0.05 mg/mL. 
 
MxiH Δ5 Freshly Prepared 2 wks, 4 oC 2 wks, 40 oC 
Prior to Elution 0.001 0.001 0.000 
10 mM Histidine 0.003 0.002 0.014 
0.5 M NaCl 0.001 - - 
0.75 M NaCl 0.002 - - 
1.0 M NaCl 0.002 - - 
2.0 NaCl 0.005 - - 
3.0 M NaCl 0.001 0.000 - 
1.0 M Gdn HCl 0.003 0.003 0.001 
1.0 M NaCit 0.143 0.091 0.039 
1.0 M NaPhos 0.201 0.160 0.078 
70 mM SDS 0.088 - - 
PrgI Δ5    
Prior to Elution 0.001 0.002 0.002 
10 mM Histidine 0.003 0.003 0.000 
0.5 M NaCl 0.001 - - 
0.75 M NaCl 0.002 - - 
1.0 M NaCl 0.004 - - 
2.0 NaCl 0.003 - - 
3.0 M NaCl 0.000 0.006 - 
1.0 M Gdn HCl 0.005 0.006 0.004 
1.0 M NaCit 0.137 0.081 0.036 
1.0 M NaPhos 0.197 0.151 0.092 
70 mM SDS 0.056 - - 
BsaL Δ5    
Prior to Elution 0.001 0.002 0.002 
10 mM Histidine 0.004 0.003 0.003 
0.5 M NaCl 0.000 - - 
0.75 M NaCl 0.001 - - 
1.0 M NaCl 0.006 - - 
2.0 NaCl 0.003 - - 
3.0 M NaCl 0.000 0.000 - 
1.0 M Gdn HCl 0.002 0.005 0.002 
1.0 M NaCit 0.171 0.105 0.036 
1.0 M NaPhos 0.196 0.154 0.082 
70 mM SDS 0.100 - - 
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in both cases, the quantity eluted represented only approximately 75% of the total 
protein.  At an increased incubation temperature of 40 oC, the results were similar, but the  
quantity eluted was further reduced to less than half of the original amount.  These 
observations suggest that interactions occurring upon initial adsorption change with time 
as the protein establishes new contacts with the surface [30].  Given the lack of elution in 
the presence of high salt concentrations and the strongly hydrophilic nature of the 
proteins and the surface, we hypothesize that adsorption probably involves Van der 
Waals interactions and/or hydrogen bonding. 
 
 3.3.4  ELISA 
 To examine the stability of the adsorbed product, we employed a standard ELISA 
method.  Unfortunately, only Anti-PrgI Δ5 antibodies were available and therefore only 
the PrgI formulation was studied in this manner.  We were particularly interested in 
evaluating the effect of decreased protein desorption over time in terms of changes in the 
protein as detected by interaction with a specific antibody.  We therefore compared the 
antibody binding of solution protein to that of adsorbed protein which had either been 
stored at 4 or 40 oC for > 6 months.  As shown in Figure 5, no significant difference 
(p<0.0001) in interaction with antibody was observed for PrgI Δ5 in solution and an 
adsorbed sample stored for 6 months at 4 oC.  A second sample which had been stored at 
40 oC, however, did display a significantly lower response than both the solution material 
and the adsorbed material stored at 4 oC.  This result suggests loss of at least one epitope 
upon long-term storage at elevated temperatures.      
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Figure 3.5 Absorbance values observed at 450 nm when each sample was plated and 
analyzed by a standard ELISA protocol. 
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3.3.5  Capillary liquid chromatography-mass spectrometry analysis and protein mapping  
To further examine the difference observed by ELISA between the adsorbed PrgI Δ5 
formulations stored at 4 vs. 40 oC, we eluted protein from the adjuvant surface using 1.0 
M Sodium Phosphate and obtained a peptide map for both samples.  We also acquired a 
map of the solution protein which had been frozen since production.  Although the 
coverage was not optimal due to the presence of several small peptides, all residues 
commonly associated with chemical degradation reactions were covered and no changes 
were observed in either of the adsorbed samples (Figure 3.6).  This suggests that the 
decrease in antibody binding observed in the ELISA assay was due to a change in protein 
conformation as opposed to an alteration in primary structure. 
 
3.4  Discussion 
As described above, previous work has thoroughly defined the solution stability 
of each of the three proteins over a range of pH 3-8 and under thermal stress.  We found 
that these mutant proteins, which are composed of helix-turn-helix structural elements, 
are sensitive to pH, thermally labile and have reversible thermal transitions.  
Additionally, they display molten globule-like behavior in the physiological temperature 
range which may be critical to their transport through the growing needle structure given 
its limited diameter of 2.0-3.0 nm.   
Here we have further characterized the proposed vaccine antigens for the 
purposes of formulation development.   Excipient screening indicates that their thermal 
stability is increased by the presence of polyols and carbohydrates probably by the well  
 79 
 
A. 
 
B. 
 
C. 
                                                                                                                          
Figure 3.6 Peptide maps for (A) untreated PrgIΔ5 (B) PrgI Δ5 eluted from aluminum 
hydroxide surface following 6 mos of incubation at 4 oC and (C) PrgI Δ5 eluted from 
aluminum hydroxide surface following 6 mos of incubation at 40 oC. 
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described mechanism of preferential hydration [27].  Binding isotherms for each antigen 
to aluminum hydroxide were also presented.  In all three cases, data was well described 
by the Langmuir equation with adsorptive capacities in the range of 1.56-1.72 mg/mg 
aluminum.  The proteins do not appear to interact with aluminum hydroxide through 
electrostatic interactions despite their highly charged surfaces, but rather that hydrogen 
bonds, Van der Waals or apolar forces are involved.  Additionally, a time-dependent 
change was observed in the desorption profile of adsorbed proteins.  These changes in 
adsorption behavior were characterized over time using both an ELISA method and 
peptide mapping for one of the proteins.  ELISA results indicated a difference in the 
antibody binding ability of the adsorbed protein stored for ~ 6 mos at 40 oC while no 
change was observed at 4 oC.  Peptide maps of the adsorbed protein indicate that relative 
to the protein primary structure prior to adsorption; no chemical changes in amino acids 
were observed.   
Concurrent with this work, a second protein integral to the TTSS has also been 
developed as a potential vaccine candidate.  This protein, often referred to as the ‘tip’ 
protein, has been shown in Shigella to transverse the needle and reside at the distal tip 
during the initial stages of infection [28].  Many groups have shown this protein from the 
Shigella system, IpaD, to be highly immunogenic [29].  Additionally, antibodies specific 
to this protein have been shown to neutralize host-cell infection by Shigella suggesting 
protective behavior [28].  It is interesting to note that the excipients which provided the 
greatest degree of thermal stabilization for the needle proteins were similar to those 
which stabilized the tip proteins (Markham et al, unpublished results), and that both 
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groups of proteins strongly adsorb to aluminum hydroxide.  We have hypothesized that a 
bivalent vaccine would be superior to a monovalent one and to that end have conducted 
initial immunogenicity studies of the two types of vaccines.  We were able to show that 
administration of a bivalent vaccine to mice containing both the needle and tip proteins 
from the Shigella system resulted in a synergistic increase in immune response relative to 
monovalent doses (submitted).   
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4.1  Introduction 
Gram-negative bacterial pathogens are responsible for millions of debilitating 
infections each year.  For example, Shigella flexneri and Salmonella spp., account for 
upwards of 165 and 200 million cases annually, respectively [1,2]. 
The Shigella species primarily use fecal-oral transmission to invade human hosts, 
most commonly via contaminated food or water.  Host-to-host spreading, however, has 
also been observed.  As a result, densely populated regions lacking proper sanitation are 
among the most heavily impacted.  Symptoms of infection include fever, vomiting, 
severe abdominal cramping and/or bleeding, diarrhea and dysentery.  Immuno-
compromised populations, including the young and elderly, are more susceptible to 
serious complications arising from infection, which may ultimately result in death.  
Salmonella spp. also infects via the fecal-oral route with symptoms similar to those of 
Shigella; however, select serotypes are also known to induce bacteremia [3].  While 
Shigella infections are more common in developing nations, high profile food-borne 
Salmonella outbreaks are increasingly frequent in the U.S. [4, 5]. 
Due to the frequency and severity of disorders caused by gram-negative bacteria, 
and their prevalence in the developing world, an inexpensive efficacious vaccine is a 
leading priority.  This need is further emphasized by the emergence of antibiotic resistant 
strains over the last twenty years.  For instance, in separate studies of Shigella outbreaks 
in Kenya and Chile, resistance to Ampicillan was more than 80% percent [6,7].  Also 
observed in Kenya, 47% of isolated Salmonella species were resistant to at least 3 
commonly used antibiotics [8].   In the developed world, drug resistance is also on the 
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rise.  In the United States, the number of drug-resistant strains has risen from 0.6% to 
34% in a sixteen year period [9].   
These two pathogens have in common Type Three Secretion Systems (TTSS) 
which facilitate host cell invasion.  TTSS complexes are composed of more than 20 
proteins organized in basal and extracellular regions which span the inner and outer 
bacterial membranes.  They protrude approximately 60 nm from the bacterial surface [10, 
11].  The extracellular portion is commonly referred to as the ‘needle’ for its tubular 
geometry and involvement in transporting effector proteins directly from the bacterial 
interior to the host cell cytoplasm.  The needle is primarily composed of approximately 
120 copies of a repeating polymeric unit arranged in a helical array [10, 11].  The subunit 
(MxiH, Shigella flexneri and PrgI, Salmonella spp.) is a small (9-10 kDa) protein 
composed largely of alpha helical structure.  On the distal needle tip lies a multimer 
which regulates secretion of the effector proteins [12].  The monomer (IpaD, Shigella 
flexneri and SipD, Salmonella spp.) is a slightly acidic dumbbell shaped protein (35-37 
kDa) with a coiled coil at its center [13, 14].   
Here we focus on the needle (MxiH and PrgI) and tip (IpaD and SipD) proteins as 
potential vaccine antigens due to their surface exposure and essential function during 
infection.  It is thought that antigens with repeating epitopes are more immunogenic than 
those possessing only a single recognition site [15].  Additionally, increased antigen size 
has been shown to increase immunogenicity.  For this reason we chose to formulate a 
recombinant polymeric needle construct which mimics the TTSS structure.  This would 
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be combined with tip proteins to create a vaccine with multi-valency and multi-epitope 
specificity. 
Vaccine research directed toward these two pathogens has primarily focused on 
employing lipopolysaccharide (LPS) and attenuated bacteria, with limited success [16, 
17].  In general, vaccines for Salmonella have focused on prevention of enteric fevers 
such as typhoid, but little work has been done to combat non-typhoidal indications [16, 
18, 19].  In the case of Shigella, both an attenuated form of the bacteria as well as a 
formulation containing an O-polysaccharide linked to a carrier protein have reached 
Phase III clinical trials, but have not yet attained approval [17].  Significant work has also 
been done on IpaD, the tip protein from the Shigella system.  Several groups have shown 
IpaD to be immunogenic [20], and most recently that antibodies raised against IpaD 
neutralize host-cell invasion of Shigella in-vitro [12].  Furthermore, epitope mapping has 
been completed for IpaD, which indicates that immune responses are greater in the 
amino-terminal region [20].  In the same study, it was noted that the Salmonella analog, 
SipD, shares significant sequence homology with the C-terminal region of IpaD.  Thus, it 
is possible that the epitopic response in these regions may provide a degree of cross-
protection [20]. 
Another bacterium for which vaccine efforts have focused on TTSS components 
is Yersenia pestis.  In this case, work has focused on subunit forms of the F1 capsular 
antigen and LcrV, the TTSS needle tip protein.  Both have been proven immunogenic and 
protective, although development has been slowed by several factors including a 
demonstrated immuno-suppressive effect of LcrV on innate immunity [21-24].  
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Regardless, it has been established that LcrV activates dendritic cells (DCs) [25].  Similar 
to the work indicated here, the needle component, YscF, has also been considered as a 
vaccine antigen for this species.  The wild type needle protein was shown to elicit a 
strong antibody response, and provide a degree of protection (60%) upon challenge [26, 
27].  In contrast to the protective effect of antibodies to IpaD, anti-YscF does not inhibit 
translocation of effector proteins suggesting that its protective effect is probably due to 
opsinization and/or enhanced complement binding [26]. 
The work presented represents an initial attempt to develop human vaccines for 
two of these pathogens.  To this end, we have selected an approved adjuvant, aluminum 
hydroxide, to include in our proposed recombinant subunit formulations. 
 
4.2 Materials and Methods 
 
4.2.1  Vaccine 
Recombinant proteins were expressed in E. coli as described previously [28-31].  
The needle proteins (MxiH and PrgI) were expressed with a five residue C-terminal 
truncation to prevent inherent polymerization and ensure monomeric behavior.  
Additionally, MxiH was expressed in its full length form, resulting in largely 
polymerized material referred to as ‘needle’ hereafter (data not shown).  All proteins 
were purified by means of a C-terminal His6 tag, and dialyzed to 10 mM Histidine, 144 
mM NaCl buffer at pH 6.0.  Proteins were adsorbed to aluminum hydroxide, a positively 
charged aluminum salt adjuvant, at a concentration of 0.5 mg/mL aluminum by stirring at 
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4 oC.  In bivalent formulations, the solution materials were mixed, and the adsorption step 
was performed subsequent to mixing.  Characterization and analysis of each formulation 
are documented elsewhere (in preparation).  In all cases complete adsorption (>95%) of 
the antigens was observed.    
 
4.2.2  Animals and Immunization 
Animal studies were performed at the University of Kansas in accordance with 
regulations set forth by the Institutional Animal Care and Use Committee and guidelines 
of the Association for Assessment and Accreditation of Laboratory Animal Care.  For all 
experiments, BALB/c mice were acquired from Charles River Breeding Laboratory 
(Wilmington, MA) and quarantined for 7 days prior to study start.  Inoculations (100 µL) 
were administered intramuscularly on study days 1, 14 and 28 and mice were bled via the 
submandibular vein on days 0, 7, 21, 35 and 49.  Weights were recorded at each time-
point and monitored for indications of adverse effects due to dosing, however none were 
observed.  Mice were euthanized following the final bleed on day 49.   
In the first study, each group contained 10 mice (5 female and 5 male) with the 
exception of the histidine buffer control group which contained only 7 mice.  No 
significant differences were observed in end-point titers between male and female mice.  
Formulations containing only one antigen (MxiH or IpaD) were dosed at 1 (M1, D1), 10 
(M10, D10) and 50 (M50, D50) µg/dose, while formulations containing both antigens 
(MD1, MD10 and MD50) were administered at the same total protein concentration (1, 
10 and 50 µg protein/dose); containing one-half the amount of each.  The two control 
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groups were dosed with either formulation buffer or 0.5 mg/mL aluminum in formulation 
buffer. 
Study 2 contained groups of 7 mice (female), and a single control group 
containing 5 mice (0.5 mg/mL aluminum in isotonic His buffer).  MxiH, MxiH Needle 
and IpaD were all dosed separately at 10 µg, both in the formulation buffer as well as 
adsorbed to aluminum hydroxide (M-Soln, M-His, N-Soln, N-His, D-Soln and D-His 
respectively).  Bivalent formulations containing IpaD and either MxiH or Needle were 
administered adsorbed to aluminum hydroxide at total protein concentrations of 20 
µg/mL (10 µg of each). 
The third study, conducted concurrently with study 2, involved groups of 8 mice, 
and a control group of 5 mice (0.5 mg/mL aluminum in isotonic His buffer). Monovalent 
formulations of both PrgI and SipD were administered at 1, 10 and 50 µg/dose (P1, P10, 
P50, S1, S10 and S50), while bivalent formulations were dosed at total protein 
concentrations of 2, 20 and 100 µg/dose (PS1, PS10 and PS50).  Non-adsorbed 
formulations were also administered at 50 µg for PrgI, SipD and the bivalent combination 
(P50-Soln, S50-Soln and PS50-Soln).     
 
4.2.3  IgG Detection in Serum Samples 
Antigen specific IgG titers were determined for individual sera samples using a 
standard Enzyme Linked Immunosorbent Assay (ELISA).  The optimal protocol differed 
for the needle (MxiH and PrgI) and tip (IpaD and SipD) proteins.  Needle proteins were 
adsorbed (100 µL) onto Nunc-Immuno™ MediSorp™ (Nalge Nunc International, 
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Wiesbaden, Germany) 96-well plates at 10 µg/mL in carbonate buffer (pH 9.6) overnight 
at 4 oC.  Plates were blocked with Superblock per product instructions.  Sera dilutions 
(100 µL) were made using the blocking buffer and allowed to incubate on the plate for 2 
hours at RT.  The plates were then washed 3 times using PBS buffer containing 0.05% 
Tween 20, and a final time with PBS buffer alone.  HRP-conjugated Goat anti-Mouse 
Monoclonal Antibody (Sigma, St. Louis, MO) was diluted 1:500 in blocking buffer, 
plated (100 µL) and incubated for 1 hour at RT.  The plates were then washed as above, 
and 3,3’5,5’-TetraMethylBenzidine (TMB) substrate (100 µL) (Sigma, St. Louis, MO) 
was added.  After 30 minutes at RT, 2 M HCl (100 uL) was added to quench the reaction 
and plates were read using a SpectraMax M5 plate reader (Molecular Devices, 
Sunnyvale, CA) at 450 nm.   
Tip proteins were adsorbed (100 µL) onto Costar® non-treated black with clear 
bottom plates (Corning Life Sciences, Lowell, MA) at 10 µg/ml in carbonate buffer 
overnight at 4 oC.  Plates were blocked with casein buffer (pH 7.5) for 30 min. 
Subsequent steps were the same as those for the needle ELISA protocol with the 
exception that the casein buffer was used in place of the Superblock.  In all cases, 
endpoint titers were determined as the inverse of the dilution with optical density at 450 
nm greater than 3 times the negative control. 
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4.2.4  Statistical Analysis 
The geometric mean was used to represent group responses, and error was 
determined as the standard deviation.  Statistical significance was determined with 
Student’s t-test using Microsoft Excel.  Significance was determined as p ≤ 0.05.  
 
4.3  Results  
 
4.3.1  Generation of Humoral Response 
Mice were intramuscularly immunized three times at two week intervals (study days 1, 
14 and 28), and blood samples were collected via the submandibular vein on days 0, 7, 
21, 35, and 49.  For all cases, in which significant increases in IgG were observed, all 
mice had endpoint titers within two dilutions of the geometric mean.  Figures displaying 
individual titers for each experiment can be found in Supplemental Data.  On day 0 of the 
first experiment, all mice had Anti-MxiH IgG titers near 128 (Figure 4.1A).  Mice in the 
control group maintained a similar value throughout the study.  Animals dosed with 1 µg 
of MxiH (M1) showed only a slight increase in antibody response throughout the study 
(p<0.02, day 49 compared to day 0), while those administered a 10 µg dose (M10) 
showed some response after the second booster compared to the control groups 
(p<0.0015).  Mice who received the highest dose of 50 µg (M50) displayed an increase in 
serum IgG following the initial dose (p=0.0002), and continued to increase following the 
two booster injections.  Those animals who received bivalent doses of 1 µg (MD1) did  
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Figure 4.1 Geometric mean anti-MxiHΔ5 (A) and IpaD (B) IgG serum responses 
following intramuscular injections on study days 1, 14, 28 of Control (■), M1/D1 (■), 
M10/D10 (■), M50/D50 (■),MD1 (□), MD10 (□), MD50 (□).  Endpoint titer values for 
anti-MxiHΔ5 (C) and IpaD (D) IgG. 
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not show a significant increase in Anti-MxiH IgG during the experiment (p<0.0001); 
however, when the dose was increased to 10 µg (MD10) an increased response relative to 
the control groups was observed after the initial dose and rose again following the first 
and second boosters.  The largest bivalent dose of 50 µg (MD50) resulted in a 
dramatically increased response relative to the lower bivalent and all monovalent groups.  
In all cases, the responses observed following the second booster were sustained for three 
weeks after the last injection. 
When assayed for Anti-IpaD antibodies at day 0, all mice had endpoint titers of 
approximately 32, and those mice in the control groups continued at a similar low level 
throughout the remainder of the experiment (Figure 4.1B).  Mice which were injected 
with 1 µg of IpaD (D1) showed a slight increase in IpaD IgG following the first injection 
(p<0.05) followed by an increase of greater than 10 dilutions after the first booster.  The 
10 µg dose (D10) showed a larger increase in antibody titer compared to the 1 µg dose 
following the initial injection, and a similar increase following the first booster.  The 50 
µg dose (D50) followed the same trend with higher endpoints following the first two 
doses relative to the two lower dose groups.  IgG titers for IpaD when administered in the 
presence of MxiH (MD 1, 10, 50) are analogous to those observed when IpaD was dosed 
alone.  The only significant difference occurs following the initial injection, where the 
bivalent dosed mice have higher IgG titers than those who received IpaD alone.  As seen 
with the MxiH IgG responses, those observed for IpaD following the second booster 
remained at a comparable level for all groups when sampled on study day 49. 
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The second and third studies followed the same immunization and blood 
collection schedule as the initial experiment.  In the second study, all monovalent doses 
were 10 µg while those containing both antigens had 10 µg of each included.  Similar to 
the initial experiment, all mice had Anti-MxiH IgG endpoint titers of approximately 256 
on day 0, and the control group maintained similar values throughout the study (Figure 
4.2 A).  Those animals who received a 10 µg dose of MxiH in formulation buffer (M-
Soln) did not show a significant response throughout the entire study.  When the same 
dose was administered adsorbed to aluminum hydroxide (M-Al), again no response was 
observed.  In the presence of IpaD, however, an increase in Anti-MxiH IgG was observed 
following the second booster (p<0.0001).  A significant Anti-MxiH IgG response was 
observed following the initial injection and further increased following the first booster 
when mice were inoculated with the polymerized form of MxiH in solution (N-Soln.).  
The responses observed following the second booster increased only slightly (p<0.05).  
When the same dose was administered adsorbed to the adjuvant (N-Al), a similar trend 
was observed with increased magnitude.  In the presence of IpaD, the response was 
identical to that in its absence with the exception of the response following the initial 
injection which was slightly higher in the presence of IpaD. 
The anti-IpaD endpoint dilution for all mice prior to the first injection of study 2 
as well as mice in the control group throughout was 32 (Figure 4.2B).  Mice inoculated 
with a 10 µg dose of IpaD in solution (D-Soln) displayed a significant response following 
the first and second injections and maintained the IgG titer thereafter.  When adsorbed to 
aluminum hydroxide (D-Al), the same response trend was observed but with a higher  
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Figure 4.2 Geometric mean anti-MxiH Δ5 (A) and IpaD (B) IgG serum responses 
following intramuscular injections on study days 1, 14, 28 Control (■), M-Soln/D-Soln 
(■), M-Al/D-Al (■), MD-Al (■), N-Soln (□), N-Al (□), and ND-Al (□).  Endpoint titer 
values for anti-MxiHΔ5 (C) and IpaD (D) IgG. 
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titer (p<0.004, day 49).  In the presence of monomeric MxiH (MD-Al), the initial dose 
elicited a slightly lower response than that of adsorbed IpaD alone (p<0.01), and the  
bivalent formulation did not reach the same endpoint titer following the boost injections.  
Mice given the bivalent formulation containing the polymerized MxiH displayed an 
identical profile to that of D-Al with the exception of the final time-point where the 
response was slightly lower (p<0.01).      
The final study involved analogous needle and tip proteins from Salmonella spp.  
At the study start, all mice displayed PrgI specific IgG endpoint titers of approximately 
64 (Figure 4.3A).  The control group displayed a similar value throughout the study.  
Mice given the 1 µg dose of PrgI (P1) demonstrated an increase in titer over the course of 
the experiment (p<0.005, day 49 compared to day 0).  The mice inoculated with 10 µg 
(P10) displayed an increase following the first dose, and levels rose somewhat during the 
remainder of the experiment.  The mice in the highest aluminum hydroxide adsorbed 
dose group (P50), had increasing titers following each injection, while in the absence of 
aluminum hydroxide (P50-Soln), the response was comparable to that of P1 and P10.  
When dosed in the presence of SipD, the response to 1 µg (PS1) is slightly higher at day 
21 (p<0.05), but similar thereafter to P1.  At 10 µg (PS10), the PrgI IgG endpoints 
mirrored that of the antigen in the absence of SipD.  At the highest dose level (PS50), the 
response followed a similar trend to that of the P50 treated mice, although the level was 
not as great following the second boost injection.  The bivalent 50 µg solution dose 
(PS50-Soln) had similar values to that of the monovalent solution dose (P50-Soln) with  
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Figure 4.3 Anti PrgI (A) and SipD (B) IgG serum responses following intramuscular 
injections on study days 1, 14, 28 of Control (■), P1/S1 (■), P10/S10 (■), P50/S50 (■), 
P50-Soln/S50-Soln (■), PS1 (□), PS10 (□), PS50 (□) and PS50-Soln (□). 
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the exception of day 7 where P50-Soln mice were slightly higher than PS50-Soln 
(p<0.05). 
The endpoint titers in the SipD groups of Study 3 were roughly 16 prior to 
injections (Figure 4.3B).  Mice given 1 µg doses of SipD (S1) demonstrated a slightly 
elevated endpoint after the first injection, but experienced a boost of more than 5 
dilutions following the second dose.  Mice in the 10 µg dose (S10) group followed a 
similar trend with increased endpoint titers at each time-point.  The 50 µg (S50) dose did 
not elicit a significant difference in antibody response compared to that of S10 treated 
mice with the exception of day 7 where S50 was greater (p<0.01).  When no aluminum 
hydroxide was present (S50-Soln), the response to the initial injection was comparable to 
that observed for S10 and S50.  Following the booster doses, however, the increase in 
antibody levels was not as great.  The 1 µg bivalent formulation (PS1) followed the trend 
observed for the monovalent (S1) formulation, but with lower antibody values.  The 10 
and 50 µg combination doses (PS10 and PS50) also behaved similarly to their 
monovalent analogues, S10 and S50, but with lower titers at all time-points.  When the 
bivalent formulation was injected in the absence of aluminum hydroxide (PS50-Soln), the 
observed response was lower than that of the S50-Soln group throughout the study.  
 
4.4  Discussion 
In the present study we have demonstrated the immunogenicity of TTSS needle 
and tip proteins both in monovalent and bivalent formulations.  Additionally, no adverse 
effects were observed throughout the dosing regimen as indicated by normal weight gain 
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patterns (data not shown).  In all studies where increases in specific antibody titers were 
observed, there were no non-responders suggesting that the formulations may be 
efficacious if IgG levels are predictive of protection. 
MxiH monomer has shown to be weakly immunogenic and dose dependent, 
requiring fairly high doses of antigen, multiple boosts and the presence of an adjuvant to 
elicit a strong response.  When administered in the presence of IpaD, however, the Anti-
MxiH specific IgG was significantly boosted.  This enhanced response does not appear to 
be the result of physical interaction between the two proteins when combined in solution 
(data not shown.) It is possible however that the presence of aluminum hydroxide 
provides a platform for interaction between the two.  It is also possible that IpaD has 
inherent adjuvant-like properties as evidenced by its sizeable immunogenicity when 
dosed alone in the absence of an adjuvant. 
The polymerized form of the needle protein, expressed without the C-terminal 
truncation, is drastically more immunogenic than the monomeric version.  There exists a 
well established correlation between antigen size and immune response [15].  Thus, it is 
possible that the increase observed here is a result of the increased size of the polymeric 
version of the needle monomer.  Another possibility is the existence of repeating epitopes 
in the polymeric unit which has also been shown to greatly increase immunogenicity.  
Finally, it is also possible that the 5 residue C-terminal region which is absent in the 
monomeric form constitutes a potent epitope.  Similar to the monomeric version, the 
response of the polymerized form is further boosted by adsorption to an adjuvant. 
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The tip protein from the Shigella system is shown here to be highly immunogenic 
in agreement with previous work [20].  In contrast to the needle monomer MxiH, IpaD 
does not show significant dose-dependent behavior when administered in a multi-dose 
regimen; however there does appear to be an indication of dose-dependency following 
the first inoculation.  As stated above, it is possible that due to its potent immunogenicity, 
IpaD may act as an adjuvant in multivalent formulations.  While IpaD is strongly 
immunogenic alone, it does benefit from adsorption to aluminum hydroxide.  
Antigens from the Salmonella system also appear to elicit substantial immune 
responses.  Similar to the results observed for the Shigella system, the monomeric needle 
protein PrgI is less immunogenic than the tip protein SipD.  PrgI displays dose dependent 
behavior, and titers increase markedly when booster doses are administered.  As one 
would expect, IgG responses to PrgI are enhanced when the antigen is adsorbed to 
aluminum hydroxide.  Contrary to the immune response to MxiH seen in the presence of 
the analogous tip protein, however; PrgI does not produce higher antibody levels in the 
presence of SipD.   
Mice injected with SipD had high antibody titers following the first dose and were 
relatively dose independent after the first booster injection.  This trend is similar to that 
observed for IpaD, but in all cases, responses to SipD were lower in magnitude.  
Additionally, where IpaD was boosted slightly by the presence of MxiH, SipD titers 
appear to be reduced when administered in the presence of PrgI.  Despite differences in 
primary sequence, this observation is strikingly similar to the documented immuno-
suppressing activity associated with LcrV, the tip protein of Yersinia pestis [24]. 
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While the studies presented here support further vaccine development utilizing 
TTSS needle and tip proteins, further work is clearly necessary.  Additional studies will 
focus on tailoring the formulation to elicit an appropriate response based on the 
pathogenesis of each species to ensure protection.  Salmonella spp. bacterial infections 
often result in systemic invasion, which are responsible for some of the most severe 
symptoms [3].  Preventing a systemic infection may be possible using versions of the 
formulation studied here which was dosed intramuscularly.  While no data is currently 
available to definitively associate the presence of PrgI/SipD specific IgG with protection, 
needle proteins have been shown to enhance well-established opsinization phenomenon 
and in-vitro studies suggest that tip protein antibodies prevent host-cell invasion [12].  
In contrast, Shigella infections generally involve the epithelial cells of the 
intestines and do not commonly result in septicemia.  This suggests that a vaccine will 
need to protect the mucosal surfaces to be effective.  It is not yet certain whether the 
current formulation will meet this requirement.  To explore this question, it will be 
necessary to conduct additional immunogenicity experiments focusing on IgA levels.  
Other tests which may be necessary include evaluation of cellular responses and 
associated adjuvants and the effect of the route of administration.  In this study, an 
aluminum salt adjuvant was chosen because it is currently the only FDA approved 
vaccine adjuvant.  Novel adjuvants are now becoming available, however, and they will 
need to be examined in this system [32-35].   
As previously stated, the main purpose of the work presented here is to establish 
the antigenic potential of TTSS needle and tip proteins.    We have shown here that 
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administration of these proteins results in robust humoral immune responses.  Based on 
previous work, this may be sufficient for protection.  While some bivalent formulations 
did not have a synergistic effect, we propose that the multivalent approach may be 
advantageous for several reasons including increased likelihood of protection across 
populations and potential cross-protection among similar species.  In summary, work 
shown here supports the development of TTSS proteins as antigens in multivalent subunit 
vaccines.   
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5.1  Introduction 
Ricin toxin is widely recognized as a potential bioterrorism agent due to its ease 
of acquisition and distribution as well as its stability and potent toxicity.  Perhaps the 
most disturbing aspect of a possible ricin attack is human vulnerability given the non-
existence of both preventative and therapeutic treatment.  Several ricin vaccine 
candidates have been identified and investigated, however, all have been hindered by 
concerns of antigen toxicity and none have reached the commercial market [1-5].   
Ricin, an exotoxin found in the seeds of the castor bean plant (Ricinus communis), 
is a 64 kDa heterodimer composed of a ribotoxic A (RTA) and a lectin binding B chain 
linked by a single disulfide bond [6].  The protein dimer belongs to the family of 
ribosome inactivating proteins (RIPs) and is synthesized as a single polypeptide chain 
which is enzymatically cleaved inside the seed to produce the toxic dimer form.  During 
exposure, the B chain binds galactose residues of the cell surface glycolipids and 
glycoproteins, facilitating endocytosis of the holotoxin.  Once inside the cell, the 
disulfide bond maintaining the dimer is reduced and the enzymatic A chain escapes the 
Golgi to the cytosol.  There it disrupts cellular protein synthesis by depurinating a 
specific adenine of the 28s ribosomal RNA subunit [7-11].  Due to its catalytic activity, a 
single molecule of ricin can significantly inhibit cellular protein synthesis and ultimately 
induce cell death.  A lethal human dose is in the range of 1-10 µg/kg for aerosol delivery 
and slightly higher for oral delivery.  Within 4 hours of lethal exposure, the condition is 
irreversible and death ensues within 4-5 days [8, 9, 12]. 
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The A chain (RTA) is an attractive vaccine candidate given its ability to induce a 
protective immune response against ricin challenge and its intimate involvement during 
infection [1, 12, 13].  It is however, associated with dose limiting toxicity due to its 
ribotoxic activity and ability to induce Vascular Leak Syndrome (VLS) in humans [14].  
The toxic nature of RTA can be eliminated by mutating two specific residues (V76M and 
Y80A), one in each of the enzymatic sites [13, 15, 16].  The resulting recombinant 
mutant, RiVax®, has no associated toxic activity as evaluated by toxicology studies in 
rabbits, retains all immunodominant epitopes, and maintains the protein’s native structure 
as well as its ability to induce protection against a ricin challenge [13, 16-18].   
As expected for a recombinant protein antigen, it has been shown that the 
presence of an adjuvant greatly increases the immunogenicity of rRTA over soluble 
material [1].  Additionally, previous work has shown that RiVax® efficiently adsorbs to 
aluminum hydroxide.  Here we present optimization of an aluminum hydroxide adsorbed 
RiVax® product [19].  It is widely accepted that the stability profiles of biological 
molecules are complex and often understood only to a limited degree.  In the specific 
case of aluminum adsorbed vaccine formulations, the comprehensive characterization of 
adjuvant-antigen interactions is essential for understanding product stability, yet can be 
difficult to achieve given the opaque nature of the suspensions.  In solution, a wide range 
of physicochemical assays can be used to determine product stability, consistency, and 
potency.  In the presence of an aluminum salt such as aluminum hydroxide, however, 
many of the more commonly used methods are not applicable and only a limited number 
of specialized techniques are available to directly probe the stability of such vaccines.  
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Examples of such stability relevant techniques include, but are not necessarily limited to 
immune correlates (ICs), Enzyme-Linked Immunosorbent Assay (ELISA), Front-face 
Fluorescence emission (ff-Fluorescence), Fourier Transform Infrared Spectroscopy 
(FTIR) and Differential Scanning Calorimetry (DSC).  Here we employ ff-Fluorescence 
as a stability indicating assay for aluminum hydroxide adsorbed RiVax® and present 
associated stability studies.        
 
5.2  Materials and Methods 
 
5.2.1  Materials 
Isotonic histidine buffer (10 mM) was prepared using L-histidine 
monohydrochloride monohydrate (Sigma) and Sodium Chloride (144 mM) (Sigma) and 
adjusted to pH 6.0 with 6 N Sodium Hydroxide.  Aluminum hydroxide (2%) was 
obtained from E.M. Sergeant Pulp and Co., Inc. (Clifton, NJ), and RiVax® was received 
from Cambrex BioScience (Baltimore, MD) in a highly purified form (>95% pure) [19].  
All other chemicals used were of scientific grade. 
 
5.2.2  Preparation of solution RiVax® 
 RiVax® was extensively dialyzed at 4 oC into isotonic Histidine buffer at pH 6.0 
using SpectraPor Dialysis Membrane (Spectrum Labs, MWCO 10 kDa).  It was then 
concentrated using an Amicon Ultra Centrifugal Filter Device (Millipore, MWCO 30 
kDa) and protein concentration was determined using UV absorbance spectroscopy with 
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an Agilent 8453 UV-Visible diode array spectrophotometer (Palo Alto, CA).  Protein 
concentration was determined using the absorbance value at 280 nm and an extinction 
coefficient of 0.77 (cm*mg/mL)-1.   
 
5.2.3  Preparation of adsorbed RiVax® 
The concentrated RiVax® solution prepared above was combined with stock 
aluminum hydroxide (10.1 mg/mL) in volumes calculated to deliver 0.2 mg/mL RiVax® 
in 0.85 mg/mL aluminum.  The solution was stirred gently on a stir plate at 4 ºC for > 1 
hour, and subsequently aliquoted into microcentrifuge tubes (1 mL).  A corresponding 
blank solution was prepared in the same manner and aliquoted in the same manner.   
 
5.2.4  Stability Studies 
Samples and blanks prepared as described above were placed in incubators set at 
40, 25, or 4 oC (Isotemp Fisher Scientific, Kendo Laboratory Products, Asheville, 
EchoTherm Chilling Incubator, Torey Pines Scientific, San Marcos, Laboratory Cold 
Room, Environmental Inc., Fenton respectively).  Samples were pulled from incubation 
at designated time intervals and transferred to front-face fluorescence cuvettes for 
analysis.  Cuvettes were capped and placed back in the respective incubator overnight 
(>12 hours) in order that the adsorbed protein settled to the bottom to minimize 
variability due to settling of the adjuvant during the course of fluorescence 
measurements.  The following day, without disturbing the settled sample, the cuvette was 
placed in a PTI QuantaMaster™ spectrofluorometer with a Peltier-controlled cell holder 
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(Photon Technology International, Lawrenceville, NJ).  An excitation wavelength of 295 
nm (>95% Trp emission) was used, and intrinsic tryptophan fluorescence emission 
spectra were collected from 300-400 nm while maintaining the temperature of the cell at 
the respective incubation temperatures.    The front-face cuvettes have a triangular 
geometry which allows the collection of emission spectra despite the opaque nature of the 
samples.  The cuvettes are positioned such that the excitation beam falls fully on the 
settled slurry.  The excitation slit widths were adjusted to 4 nm, and the emission slit 
widths to 2 nm for all measurements.  Spectra were obtained in duplicate and averaged, 
although only one sample was pulled per time-point due to sample quantity limitations.  
As shown in Figure 5.1, a spectrum was also collected for the blank material and was 
subtracted from the sample spectrum to eliminate the scattering contributed by the 
presence of the aluminum hydroxide.  The subtracted data was exported into Microcal 
Origin 6.0 TM where they were processed by obtaining the wavelength at which the first 
derivative spectrum crossed the x-axis.  This emission maximum peak position was 
plotted for each sample as a function of incubation time.  In addition to the intrinsic Trp 
fluorescence, each sample was also assayed for free protein.  This was done by 
centrifuging the sample for 30 sec at 14,000 g, removing the supernatant and obtaining an 
absorbance spectrum of the supernatant to quantify the antigen remaining unbound in 
solution.  Blanks were once again used as a reference for the absorbance measurements.  
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Figure 5.1 Fluorescence emission spectra (obtained using front face cuvettes) of an 
adsorbed ‘blank’ sample, an adsorbed RiVax® sample and the resulting subtracted peak 
representing fluorescence emission of the sole Trp residue.   
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5.2.5  Elution 
 Solutions were prepared in isotonic histidine buffer and were not pH adjusted.  
Adsorbed samples were centrifuged at 3,000 g for 30 sec and the resulting supernatant 
was removed and assayed for protein content by absorbance spectroscopy.  In all cases, 
the supernatant was found to contain <10% (0.02 mg/mL) of the adsorbed protein.  For 
each of the elution solutions prepared, 1 mL was added to a vial containing the 
centrifuged aluminum hydroxide-RiVax® complex.  The resulting suspension was rotated 
end-over-end at 4 oC for 48 hours.  Samples were then centrifuged at 14,000 g for 30 sec, 
and the supernatant was assayed for protein content by UV absorbance spectroscopy.       
 
5.2.6  Adsorption Isotherms 
Adsorbed samples were prepared by adding concentrated RiVax® in isotonic 10 
mM Histidine buffer at pH 6.0 and aluminum hydroxide (stock 10.1 mg/mL) to deliver a 
known protein concentration to a known aluminum concentration (0.5-1.25 mg/mL).  The 
samples were tumbled end-over-end at 4 oC for 1 hour, centrifuged at 14,000 g for 30 sec 
and an absorbance spectrum of the supernatant was obtained.  The amount of protein 
bound was determined by subtracting the concentration in the supernatant from the 
concentration initially added.  A blank sample containing only buffer and 0.85 mg/mL 
aluminum was also prepared and used as a reference.  In some experiments, adsorption 
isotherms were generated in the presence of an added excipient or buffer component.  In 
these instances, the order of addition was RiVax®, buffer (if required), excipient, 
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aluminum hydroxide.  In all cases the solutions were stirred prior to the addition of the 
aluminum hydroxide. 
 
5.2.7  Animal Studies 
Animal studies conducted at SRI International (SRI) were performed in 
accordance with the National Research Council (NRC) Guide for the Care and Use of 
Laboratory Animals (1996) and the Animal Welfare Standards incorporated in 9 CFR Part 3, 
1991.  Swiss Webster mice (20-30 grams) were acquired from Charles River Laboratories 
and quarantined for 3 days.  Subcutaneous inoculations were completed on days 0 and 21 
and mice were bled via retro orbital sinus while under isoflurane anesthesia before study 
initiation and at day 21 and 28.   
Animal studies were also performed at The University of Texas Southwestern 
Medical Center (UTSW) and were conducted in accordance with regulations set forth by 
the Institutional Animal Care and Use Committee (IACUC) and guidelines of the 
Association for Assessment and Accreditation of Laboratory Animal Care.  Swiss 
Webster mice (weight) were intramuscularly inoculated on study days 0, 28 and 56 and 
bled retroorbitally on study days 0 and 70.  Mice in the challenge study were 
administered a 10x LD50 intra-peritoneal dose (100ng/kg) 14 days following the last 
vaccination, and subsequently weighed and monitored for indications of morbidity for 14 
days.  Mice were sacrificed when moribund or < 75% of the pre-challenge weight.   
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5.2.8  Sera Analysis 
Sera samples collected at SRI were analyzed according to the following ELISA 
method.  Polystyrene 384 well plates (Greiner Bio-One, Germany) were coated with a 10 
ug/mL RiVax® in 10 mM phosphate buffer at pH 7.8 and stored for less than one week at 
4 oC.  Plates were washed and subsequently blocked using PBS buffer containing 1% 
Caesin and 1% BSA for 2 h at room temperature.  Plates were then washed three times 
and treated with sample or standard in a dilution buffer consisting of 1% caesin, 1% BSA 
and 0.05% Tween 20 in PBS and again incubated for 2 hours at room temperature.  Plates 
were once again washed three times before the addition of HRP-Goat Anti Mouse IgG 
(Invitrogen) prepared at 1:32,000 in the dilution buffer.  After a 2 hour incubation period, 
3, 3’, 5, 5’-tetramethylbenzidine (Sigma) was added and allowed to react for 30 minutes 
before 2 N Sulfuric Acid was added and the plate was read using a Tecan GENios Plate 
Reader (Tecan Group Ltd., Switzerland).  
Sera collected at UTSW were analyzed by RIA as previously described [151, 
155].  A 20 µg/mL RiVax® solution in PBS was administered (100 µL) to 96 well plates 
(Costar, Corning, NY) and incubated overnight at 4 oC.  The plates were then washed and 
subsequently blocked with 5% fetal calf serum.  Standard dilutions and samples were 
then added and the plates were once again incubated overnight at 4 oC.  The following 
day, the plates were washed and [125I]-labeled rabbit anti-mouse Ig was added and 
incubated for 2 hours at room temperature.  The plates were then washed and read using a 
Gamma Counter (Pharmacia).   
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5.3  Results 
It has been shown previously that RiVax® strongly adsorbs appreciably to 
aluminum hydroxide while not interacting significantly with aluminum phosphate [55].  
It has also been shown that the antigenicity of the recombinant protein is greatly 
increased in the presence of an adjuvant [1].  Thus, we identified conditions under which 
>95% of the protein was adsorbed to aluminum hydroxide, which for the target dose of 
0.2 mg/mL required the use of 0.85 mg/mL aluminum in isotonic 10 mM Histidine buffer 
at pH 6.0.  RiVax® contains only one Tryptophan (Trp) residue which is buried in the 
protein’s interior.  Therefore, its intrinsic fluorescence emission represents a sensitive 
probe of the protein’s tertiary structure.   
Upon excitation at 295 nm, the fluorescence emission maximum for the native 
protein in solution is approximately 330 nm.  Upon adsorption, the emission maximum 
red shifts to approximately 333 nm suggesting that the Trp residue is in an environment 
of increased polarity presumably due to a slight conformational alteration of the protein 
on the surface (Figure 5.2).  To evaluate the stability of adsorbed RiVax®, samples were 
formulated and stored under various conditions to evaluate both real time (4 oC) and 
accelerated degradation stability (25 and 40 oC).  Samples were monitored using the front 
face fluorescence method as well as by assaying the sample supernatant for protein 
content using UV absorbance spectroscopy.  In all cases in which the sample supernatant 
is not mentioned, no significant protein presence (< 0.03 AU) was observed.  As shown 
in Figure 3, the peak position of maximum emission of the Trp residue red shifted  
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Figure 5.2 Fluorescence emission spectra for solution (____) and adsorbed (----) 
RiVax®.  Both spectra were obtained using front face fluorescence and represent a protein 
concentration of 0.2 mg/mL.  The adsorbed RiVax® spectrum was taken approximately 
12 hours following adsorption.  The emission maximum for solution RiVax® is 330.0 nm 
while that of adsorbed RiVax® is 333.6 nm.   
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Figure 5.3 Fluorescence peak position of adsorbed Rivax® with respect to storage 
time at 4 (■), 25 (●) and 40 (▲) oC.  Samples contained 0.2 mg/mL protein and 0.85 
mg/mL aluminum in isotonic 10 mM Histidine buffer at pH 6.0.  The uncertainty in 
wavelength position is estimated to be +/-0.5 nm. 
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significantly over the course of the 20 day study for formulations stored at all 3 
temperatures. This indicates that the residue was exposed to an increasingly polar 
environment due to conformational perturbation.  To further investigate this change, a 
longer term study was established under the same formulation and storage conditions.   
The long term study revealed that the protein Trp emission continued to red shift 
over extended periods of time (Figure 5.4).  This observation is not unexpected for 
protein-solid interfaces and probably depicts changes which occur as the protein 
optimizes its interaction with the surface through subtle step-wise structural changes [20].  
The effect of the observed conformational changes on the immunogenicity of the product 
was unknown from these studies.  Accordingly, animal studies were organized to further 
investigate this relationship.   
Mice were challenged with a 10x LD50 intra-peritoneal dose (100ng/kg) of active 
ricin toxin 14 days following the final administration of 3 doses ranging from 0.1-1.0 ug 
RiVax® adsorbed to 0.85 mg/mL aluminum.  The latter material was stored for 60 days at 
either 4 or 40 oC.  As shown in Figure 5.5, the total IgG responses for the samples stored 
at 4 oC correlated well with dose and protection.  The samples stored at 40 oC, however, 
did not induce the same level of antibody protection as the 4 oC samples.  Furthermore, 
they did not confer protection upon challenge.  By comparing the IgG responses and 
protection rates for the 0.1 ug (4 oC) and 1.0 ug (40 oC) samples, we see that despite 
similar IgG levels, the 4 oC samples protected the mice while the 40 oC samples did not.  
This observation suggests the loss of protective epitopes in samples  
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Figure 5.4 Fluorescence peak position with respect to storage time at 4 (■) or 40 (□) 
oC.  Samples contained 0.2 mg/mL RiVax® and 0.85 mg/mL in isotonic 10 mM Histidine 
buffer at pH 6.0.  The uncertainty in wavelength position is estimated to be +/-0.5 nm. 
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Figure 5.5 IgG and protection rates 28 days following 3/3 monthly injections with 
adsorbed RiVax® stored for 60 days at 4 or 40 oC.     
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stored at 40 oC.  The differences observed in immune response in combination 
with the observed spectral changes suggest that the altered conformational structure of 
RiVax® as monitored by intrinsic fluorescence changes may be directly implicated in the 
loss of antigenicity.    
It was unclear whether the spectral shifts induced at each temperature were 
distinct from one another or intermediates along a similar unfolding pathway.  Thus, a  
second animal study was performed to investigate the antigenicity of formulations stored 
at 4 oC for differing lengths of time (7 or 120 days).  Shown in Figure 5.6 is the response 
of the groups one week following the second of two injections.  It appears visually that a 
difference is observed in the lower dose groups.  Upon statistical analysis, however, it 
was found that the two data sets are not statistically different.  Thus, we conclude that 
upon storage at 4 oC, the vaccine does not decrease in potency.   
If the spectral shifts are either directly or indirectly related to the antigenicity of 
the product, this result would suggest that the conformational change occurring upon 
storage of the formulation at 4 oC is not severe enough to alter antigenicity, but has the 
potential to do so if, for example, a cold chain is broken.  To better understand the 
significance of the changing RiVax® conformation, we attempted to desorb the protein 
and inspect it for any chemical modifications.  We were most interested in the samples 
which had been stored for extended periods at elevated temperatures, and hoped to track 
the changes by sampling several points along the stability profile.  Samples were treated 
with one of several elution solutions and rotated end-over-end for 48 hours at 4 oC.  
Higher temperatures were not used for fear that additional chemical changes might occur  
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Figure 5.6 Endpoint titer >1/4096 28 days post vaccination for RiVax® formulations 
stored at 4 oC for 7 (▓) or 120 (░) days. 
 
 
 
 
 
 126 
 
 
 
 
 Desorption Solution Fresh 4 ºC, 30 days 40 ºC, 30 days 
None (Control) 1% 1% 1% 
2.0 M NaCl 0% 0% 1% 
3.0 M NaCl 2% 1% 0% 
1.0 M NaPhos (Mono) 34% 12% 2% 
2.0 M NaPhos (Mono) 5% 1% 1% 
1.0 M NaPhos (Di) 41% 17% 2% 
2.0 M NaPhos (Di) 27% 12% 0% 
1.0 M NaCit 0% 0% 0% 
70 mM SDS 0% 0% 0% 
1.0 M Gdn HCl 1% 0% 0% 
 
 
 
Table 5.1 Percent RiVax® desorbed following 48 hour exposure to each condition.  
Samples contained 0.2 mg/mL RiVax® and 0.85 mg/mL aluminum in 10 mM Histidine 
buffer at pH 6.0 
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and be indistinguishable from those which occurred while the protein was on the surface.  
As shown in Table 1 as well as in previous work, [19], high concentrations of Sodium 
Chloride do not desorb RiVax® suggesting that the primary interactions responsible for 
adsorption are not electrostatic in nature.  The use of SDS and Sodium Citrate was also 
unsuccessful at releasing the protein, an observation which is relatively common for 
aluminum hydroxide adjuvants [21].  Sodium Phosphate, which can compete with the 
protein for sites on the adjuvant, was the only eluent capable of releasing a portion of the 
adsorbed material.  It is interesting to note that if samples are treated approximately 24 
hours post-adsorption, approximately 40% can be desorbed by 1.0 M Sodium Phosphate.  
If, however, the samples are aged, and/or the incubation temperature is increased, the 
amount decreases significantly.  This observation is supported by the observed 
spectroscopic shifts as the product ages and confirms that RiVax® optimizes its contacts 
with the aluminum salt by slightly altering its conformation over time.  It may be that the 
exposed hydrophobic loop of RiVax® [1] is responsible for the bulk of the interaction 
with the adjuvant.  When the protein was treated with an organic solvent to investigate 
the proposed hydrophobic interactions however gross aggregation was observed [22].   
Given the loss in antigenicity associated with the conformational change, we 
attempted to prevent the shift from occurring.  To that end, we considered the use of 
various GRAS excipients and examined each for their ability to stabilize RiVax® 
structure on the surface of the adjuvant based on their capacity to inhibit a red shift in 
fluorescence emission upon storage at 40 oC.  As shown in Table 5.2, the presence of 
30% glycerol induces a greater degree of unfolding than the protein experiences in the  
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Excipient Red Shift (nm) 
NONE 2.7 
30% Glycerol 8.2 
1.0 mg/mL Phystic Acid 0.7 
0.3 M L-Arginine 1.8 
0.01% Brij 35 1.9 
Recombinant Human Gelatin 1.7 
Trimethylamine Oxide -0.3 
 
 
 
Table 5.2 Fluorescence peak position for adsorbed RiVax® samples stored at 40 oC 
for 2 days in the presence of various excipients.   
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absence of an excipient.  This is a surprising observation considering previous work on 
solution stability which predicted glycerol increased the stability of the protein [23].  
With the exception of glycerol, the remaining excipients which previously were shown to 
increase solution stability appeared to have somewhat small effects over the first two 
days of incubation.  Thus, longer duration studies were performed, but each excipient was 
found to have unfavorable effects on long term stability (data not shown). 
It has been established that due to its positive charge, aluminum hydroxide 
attracts anions from solution resulting in the formation of a double layer at its surface 
[24].  As a result, the surface microenvironment is characterized by an elevated pH 
relative to the bulk solution.  Thus, adsorbed proteins are susceptible to the potential 
physical and chemical changes (e.g. deamidation) induced by an increase in pH.  The 
magnitude of this pH change has been estimated to be approximately 2 units.  Therefore, 
RiVax® which is formulated in isotonic Histidine buffer at pH 6, may actually experience 
pH 8 conditions upon adsorption [24].  Previous work on the solution stability of RiVax® 
has shown that relative to pH 6, the protein is less thermally stable at pH 8 [19].  Perhaps 
more importantly, however, is the increased incidence of chemical degradation in the 
form of deamidation reactions at pH 8.  The surface microenvironment can, however, be 
adjusted by treating aluminum hydroxide with phosphate anion [24].  As a result of its 
higher valency, phosphate has a higher affinity for interaction with aluminum than does a 
hydroxyl ion.  Thus, if phosphate anion is added to aluminum hydroxide, it will displace 
hydroxyl anions and alter double layer formation.  This creates an aluminum hydroxide-
phosphate hybrid adjuvant with a reduced surface pH. 
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It is possible that the continuous time and temperature induced fluorescence red 
shift observed for adsorbed RiVax® is a result of the increased pH on the surface which 
produces physical and/or chemical changes.  Thus, we examined the effect of phosphate 
anion on the stability of RiVax® when adsorbed to aluminum hydroxide.  Order of 
addition studies were conducted to elucidate any differences induced by pre-treatment of 
the aluminum hydroxide versus addition of phosphate to the bulk buffer, and none were 
observed.  As shown in figure 5.7, the presence of 5 mM phosphate anion dramatically 
altered the stability profile of the formulation resulting in a consistent peak position of 
approximately 334 nm when stored at 4 oC and 337 nm when stored at 40 oC for 
approximately 4 months.        
 Although the presence of phosphate seems to prevent the gradual unfolding of 
RiVax® on the surface of aluminum hydroxide, it has a significant drawback associated 
with its use.  As mentioned above, the presence of phosphate anion on the aluminum 
hydroxide surface reduces its positive charge and modifies its surface chemistry.  
Therefore, depending on the nature of the interaction between the antigen and adjuvant, 
adsorption of the antigen may be affected.  Unfortunately, adsorption of RiVax® is 
reduced to approximately 50% in the presence of 5 mM phosphate anion relative to 95-
100% in its absence (data not shown).  As previously mentioned, the increased 
antigenicity of adsorbed rRTA relative to solution rRTA has been repeatedly 
demonstrated, and illustrates the requirement that a successful vaccine be >95% 
adsorbed.  Additionally, stability studies of the solution based material indicate that the 
product is not sufficiently stable when stored in solution for extended periods [19] (data  
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Figure 5.7 Fluorescence peak position with respect to storage time for 0.2 mg/mL 
RiVax® samples formulated on 0.85 mg/mL aluminum in isotonic 10 mM Histidine 
buffer at pH 6 in the absence of an excipient at 4 (■) vs. 40 (□) oC and in the presence of 
5 mM phosphate anion at 4 (●) vs. 40 (○) oC.  The uncertainty in wavelength position is 
estimated to be +/-0.5 nm. 
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not shown), suggesting that the adjuvant may not only be essential its immunogenicity, 
but also necessary for the long term stability of the vaccine.        
In an attempt to increase the adsorption of RiVax® to aluminum hydroxide in the 
presence of phosphate anion, the salt concentration of the buffer was modulated.  As 
expected, adsorption of RiVax® decreased in the presence of increasing salt concentration 
due to charge shielding (Figure 5.8).  By decreasing the salt concentration from 150 mM 
NaCl to 50 mM NaCl, adsorption was increased significantly, but >95% adsorption was 
not achieved.  Additionally, if the final formulation contained a reduced salt 
concentration, an additional excipient would be required to supplement isotonicity.   
Therefore, we considered the possibility that a lower concentration of phosphate 
might provide the same degree of stabilization while perturbing rRTA adsorption to a 
lesser degree.  To evaluate this, we formulated samples containing 0.2 mg/mL RiVax® 
adsorbed to 0.85 mg/mL aluminum in the presence of increasing phosphate anion 
concentration.  As shown in Figure 5.9, adsorption decreases from 95% to approximately 
50% as the phosphate concentration increases from 0 to 2 mM, but appears to saturate at 
concentrations above 2 mM.  Prior to evaluating the stabilizing potential of the varying 
phosphate anion concentrations, a second experiment was conducted.  Although most 
vaccines contain 0.5 - 0.85 mg/dose aluminum, it is acceptable to employ up to 1.25 mg 
[25].  Thus, we evaluated the adsorption of RiVax® to increasing aluminum 
concentrations in both the presence and absence of 0.5 and 2.0 mM phosphate anion.  As 
shown in Figure 5.10, RiVax® is >95% adsorbed in the absence of phosphate anion in the 
range of 0.5-1.25 mg/mL aluminum.  In the presence of 0.5 mM phosphate anion, the  
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Figure 5.8 Adsorption isotherm of RiVax® to 0.85 mg/mL aluminum in the presence 
of  5 mM phosphate anion and 50 mM NaCl (□), 150 mM NaCl (○) or 500 mM NaCl (Δ) 
where 100% adsorption is designated with the dotted line (---). 
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Figure 5.9 Effect of phosphate concentration of RiVax® adsorption.  Samples 
contained 0.2 mg/mL RiVax® and 0.85 mg/mL aluminum and the designated phosphate 
anion concentration.  
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Figure 5.10 Adsorption of 0.2 mg/mL RiVax® in the presence of 0 (■), 0.5 (▲), or 2.0 
(●) mM phosphate anion to increasing concentrations of aluminum.     
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adsorption is less than 70% to 0.5 mg/mL aluminum, but at 1.25 mg/mL aluminum 
adsorption increases to approximately 95%.  In the presence of 2.0 mM phosphate anion,  
RiVax® is reduced to approximately 70% adsorbed at the highest aluminum 
concentration.  Thus, we chose to pursue an increased aluminum concentration of 1.25 
mg/mL.  A stability study was initiated to evaluate the ability of these phosphate 
concentrations to prevent the gradual unfolding observed in its absence. 
Results from this stability study indicate a relationship between phosphate 
concentration and preservation of protein structure upon storage on the adjuvant surface.  
As shown in Figure 5.11, protein in each of the phosphate containing formulations 
manifests a difference in the level of structural change observed relative to protein in its 
absence.  It appears that 0.5 mM phosphate anion prevents only a limited degree of 
change, but that 2.0 mM protects the protein at a similar level to that of 5.0 mM 
phosphate in the previous study.  At all time-points, however, approximately 25-30% of 
the protein was detected in the supernatant of samples containing 2.0 mM phosphate 
anion.   
 
5.4  Discussion 
In addition to the stability of adsorbed RiVax®, the use of phosphate anion may 
also enhance its immunogenicity.  Recently, several groups have investigated the effect 
of the strength of interaction between antigens and adjuvant on immunogenicity and have 
established an inverse relationship between the two [26, 27.  This suggests that our initial 
formulation, which contained no additional excipient, and persisted in adsorption upon  
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Figure 5.11 Fluorescence peak position with respect to storage time for 0.2 
mg/mL RiVax® samples formulated on 1.25 mg/mL aluminum in isotonic 10 mM 
Histidine buffer at pH 6 in the absence of an excipient at 4 (■) vs. 40 (□) oC, in the 
presence of 0.5 mM phosphate anion at 4 (■) vs. 40 (□) oC and 2 mM phosphate anion at 
4 (■) vs. 40 (□) oC.  The uncertainty in wavelength position is estimated to be +/-0.5 nm. 
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elution treatment (after 30 days of storage), would offer a decreased response relative to a 
phosphate containing formulation. 
The use of ricin toxin as a biological weapon is a valid threat considering the 
absence of both protective and therapeutic countermeasures.  Previous work has 
described the production, solution characterization and stabilization of RiVax®, a double 
mutant recombinant A-chain antigen which provides protection against both aerosol and 
oral challenge without inducing toxicity [13, 17-19].  Here we have investigated the 
stability of the adsorbed protein and found that in the absence of phosphate anion, the 
protein conformation slowly changes over time to enhance its interaction with the 
adjuvant.  As the storage temperature is increased, the structural differences are greater 
and a loss of immunological protection is observed.  GRAS excipients were screened for 
stabilizing activity, but only phosphate anion was found to significantly inhibit the 
structural changes.  Reduced adsorption of the antigen associated with the presence of 
phosphate anion was overcome by reducing the phosphate concentration and increasing 
the amount of aluminum hydroxide present.  Thus, we have identified formulation 
conditions under which RiVax® is adsorbed to an aluminum salt adjuvant and remains 
structurally stable as indicated by the front face fluorescence assay.  Future work involves 
testing the efficacy of the aged phosphate containing formulations in mice. 
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6.1  Summary and Conclusions 
 
Recent trends in vaccine development are moving away from the historical 
attenuated and inactivated vaccine forms because of growing public safety concerns.  
Instead, the industry is focusing on new approaches which involve synthetically 
constructed materials such as recombinant subunit vaccines to reproducibly manufacture 
large quantities of high purity vaccine products.  Despite the decreased antigenicity of 
subunit vaccines relative to their whole cell counterparts, several FDA approved 
examples of recombinant vaccines exist and many more are currently in development.  
Presented here are data from each of several stages involved in the development of a 
recombinant subunit vaccine from the time of antigen identification to clinical studies.    
In chapter 2, we began by taking an in depth look at the applications of 
biophysical chemistry to vaccine development.  Using a multitude of spectroscopic 
techniques, we identified thermal stability boundaries over a range of pH (3-8) for a 
series of three structurally and functionally related mutated protein antigens, MxiHΔ5, 
PrgI Δ5 and BsaL Δ5, each from different gram-negative bacterial pathogens.  Using 
circular dichroism spectroscopy, we confirmed NMR structural results indicating that the 
proteins are largely alpha-helical in character.  We also found that the mutant proteins are 
all extremely thermally labile with changes in secondary and tertiary structural elements 
beginning at temperatures below 25 oC in many cases.  Furthermore, we discovered that 
the proteins displayed molten globule-like behavior in the physiological temperature 
range.  This observation was significant not only for formulation development, but also 
relevant to studies of the biological function of these proteins in their respective systems.  
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At a concentration of approximately 0.2 mg/mL, all observed thermal transitions were 
reversible and no indications of insoluble aggregation were observed using static light 
scattering techniques.  This knowledge aided us in the development of excipient 
screening assays discussed in Chapter 3. 
Using knowledge acquired during the comprehensive structural studies of each of 
the three antigens, we conducted a pre-formulation survey of several key formulation 
aspects.  We first evaluated the effect of a series of ‘generally regarded as safe’ (GRAS) 
compounds on the thermal stability of the antigens.  This type of assay is often commonly 
done by monitoring inhibition of protein aggregation through the use of static light 
scattering techniques.  As mentioned above, however, no insoluble aggregation was 
observed for any of the three antigens during the biophysical characterization studies.  
Therefore, we used circular dichroism spectroscopy and evaluated excipients based on 
their ability to increase the midpoint of the thermal melting (Tm).  An increase in thermal 
stability was observed for MxiHΔ5 and PrgIΔ5 in the presence of certain carbohydrates and 
polyols, and an optimal concentration of 10% Sucrose and 5% Dextrose established.  
BsaLΔ5 displayed non-sigmoidal thermal melting curves preventing the calculation of Tm 
values.  Visual analysis of the data, however, suggested that this protein was also 
stabilized by the presence of the same excipients identified for MxiHΔ5 and PrgIΔ5.  We 
next examined the adsorption behavior of each of the antigens to both aluminum 
hydroxide and aluminum phosphate adjuvants.  Given the overall acidic nature of the 
antigens (pI<5), it was not surprising to find that their interactions with aluminum 
hydroxide (PZC 11) were far greater than those with aluminum phosphate (PZC 5).  We 
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found that the nature of the interaction between the antigens and adjuvant, however, was 
not primarily electrostatic in nature, but rather appeared to be a result of hydrogen 
bonding and Van der Waals interactions among other potential interactions.  
Furthermore, it was observed that the nature of the interactions between the antigen and 
adjuvant changed over time ultimately resulting in a degree of irreversible binding.  This 
phenomenon has been observed previously [1], and is attributed to adjustments in protein 
structure resulting in the establishment of new and stronger contacts with the adjuvant 
surface.  It was unclear what effect the change in adsorption properties over time had on 
the availability of the antigen, thus we studied the interactions of the adsorbed antigens 
with specific antibodies.  We found that a decrease in interaction was observed for the 
adsorbed samples which had been stored at an accelerated temperature (40 oC), but not 
those stored at 4 oC.  In our final study, we used elution treatment and peptide mapping 
and concluded that the difference was probably structural in nature because no detectable 
changes were observed in the protein primary sequence.    
Chapter 4 presented immunogenicity data for two of the three antigens, MxiHΔ5 
and PrgIΔ5.  The experiments were performed in a murine model in which animals were 
intramuscularly inoculated 3 times at two week intervals.  Blood was collected via the 
submandibular vein and assayed for antigen-specific IgG using a standard ELISA assay.  
We found that MxiHΔ5 and PrgIΔ5 are immunogenic, and display significant dose 
dependency.  Additionally, we found that as expected, the co-administration of aluminum 
hydroxide resulted in an increased antibody response relative to inoculation with soluble 
protein.  We had previously proposed that administration of an oligomerized version of 
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the needle antigens would elicit a superior immune response relative to monomer antigen.  
We were able to confirm this hypothesis for MxiH from the Shigella system.  We also 
hypothesized that co-administration of one of the needle antigens with a second surface 
exposed protein from the bacterial system would result in a greater response than each of 
the antigens elicited alone.  We were interested to find that this hypothesis was true for 
antigens from Shigella, but not necessarily for those from Salmonella.   
The final chapter pertains to accelerated and real time studies of an adsorbed 
recombinant subunit vaccine (rRTA) for ricin toxin.  Work similar to that presented for 
the bacterial antigens in chapters 2-4 has been previously documented for this antigen by 
this laboratory [2].  Here we further investigated the effect of adjuvant surface 
adsorption, similar to the approach briefly discussed in chapter 3 for the pathogenic 
subunit antigens, for rRTA stability.  We used a fluorescence emission method which 
was not helpful in initial studies of the adsorbed bacterial antigens due to the solvent 
exposed nature of the sole Trp residue of these proteins.  Using this method for rRTA 
however, we observed a continual red shift in Trp emission indicating that with time, the 
protein was gradually unfolding on the adjuvant surface.  We also noted that the shift was 
much more rapid and extreme when storage occurred at an elevated temperature (40 vs. 4 
oC).  The efficacy of the material stored at 4 vs. 40 oC was evaluated in an animal study.  
The results indicated that despite inducing similar antibody levels, the adsorbed product 
stored at 40 oC was not protective, while the 4 oC incubated material was.  This result 
suggested that the results of the fluorescence assay may correlate with the efficacy of the 
vaccine.  Thus, we conducted accelerated excipient screening of the adsorbed antigen to 
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identify compounds which might slow or impede the loss of biological activity.  We were 
unable to identify any promising excipient candidates, but instead examined the 
possibility that an elevated pH on the adjuvant surface might be the source of physical 
alterations observed of the surface adsorbed protein [3].  We then used a previously 
documented technique [3] to reduce the surface pH by treatment with phosphate anion.  
We found that rRTA unfolding was significantly reduced by this surface modification.  
Unfortunately, the presence of phosphate resulted in a decreased adsorption capacity of 
the adjuvant causing much of the protein to remain free in solution.  Given the noted 
instability of rRTA in solution, we attempted to decrease the unbound portion by 
increasing the aluminum hydroxide content and optimizing the phosphate concentration 
to achieve the greatest stabilization with the least surface desorption.  By these actions, 
we were able to identify a stable, adsorbed rRTA formulation, and proposed animal 
studies to evaluate the efficacy of the potential product.   
 
6.2  Future Directions 
With respect to the continued development of the three bacterial antigens MxiHΔ5, 
PrgIΔ5 and BsaLΔ5, the next key task is to evaluate the efficacy of each in a murine 
protection study.  This type of experiment would involve inoculating mice with 
appropriate vaccine formulations and subsequently exposing them to the respective 
pathogens.  Although we have shown here that MxiH Δ5 and PrgI Δ5 are capable of 
eliciting a robust antibody response, this may or may not result in protection.  This 
portion of the development process will be one of the most critical for these antigens 
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because as mentioned in chapter 4, the route of infection used by each of the pathogens 
differs.  As a result, the type of immune response required for protection may also differ.  
Subsequent to challenge experiments, it may be necessary to investigate the potential for 
mucosal delivery of these antigens which would require additional animal work as well 
as formulation development.  The aluminum salt adjuvant used here was chosen because 
it is suitable for intramuscular injection and is currently the only class of vaccine adjuvant 
approved.  Intranasal delivery, however, would require a different adjuvant and therefore 
additional formulation studies.   
With respect to formulation development, there are several possibilities for further 
improvement.  First, we have shown here that administration of an oligomerized needle 
antigen results in a largely increased immune response over the monomer version, and 
thus it would be advantageous to examine possible recombinant methods for preparing 
oligomerized versions in a reproducible manner.  Secondly, using the Shigella system we 
have also shown that it may be possible to boost the immune response by administering a 
bivalent vaccine containing antigens from a single bacterial species.  However, we also 
observed a non-synergistic response when the same experiment was conducted using 
antigens from the Salmonella system.  Therefore, further development would be required 
to evaluate the advantages of this approach for each bacterial system individually.  
Lastly, it has been suggested that a single multivalent vaccine containing antigens from 
several bacterial species including Shigella, Salmonella, and Burkholderia may be 
feasible.  This type of formulation would offer several advantages over individual 
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vaccines such as increased patient compliance and the potential for cross-protection, but 
thorough immunogenicity studies would be required to confirm this. 
Further development of the vaccines would also include toxicology studies to 
evaluate safety of the vaccine, and field trials of the vaccines in highly affected regions.  
Furthermore, it may be necessary to lyophilize the formulations in order to ensure 
biological activity is maintained during transport to developing nations where the 
vaccines are greatly needed but the cold chain is inadequate. 
The rRTA vaccine is in a later stage of development than the bacterial antigens.  
A formal toxicology study has already been conducted indicating the administration of 
RiVax® is safe.  Therefore, if the phosphate containing formulation is shown to preserve 
the biological activity of the vaccine, the next step would be to manufacture the vaccine 
under GMP conditions and proceed with a non-human primate challenge study, a process 
which is underway under the guidance of DOR Biopharma Inc.  The field studies 
proposed above for the bacterial pathogens are not feasible for this type of formulation 
due to that fact that intentional exposure to the fatal toxin is obviously unacceptable, and 
there does not exist a group of people regularly exposed to the toxin.  Thus, the first 
efficacy testing in humans would be the first use of the vaccine, although hopefully this 
will never be necessary.  
I present here work toward the development of several recombinant protein 
vaccines.  Although they share some common characteristics, subunit vaccines vary 
widely from one another and each presents distinct challenges which must be addressed 
on a case-by-case basis.  The complexity of the immune system and highly dynamic 
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behavior of macromolecules make it difficult to envision the development of an empirical 
subunit vaccine formulation strategy, but it seems that if progress continues at the current 
pace, we may acquire enough data and experience to do so in the relatively near future.     
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